Latest / Masters in Business / John Carreyrou on Breaking Open the Theranos Scandal
Transcript
- 0:02Speaker 1: This is Master's in Business with Barry Ridholts on Bloomberg
- 0:06Speaker 1: Radio this weekend. On the podcast, I have an extra
- 0:11Speaker 1: special guest. His name is John Carrie Row. He is
- 0:14Speaker 1: a two time Pulitzer Prize winning investigative reporter for The
- 0:17Speaker 1: Wall Street Journal and author of the book Bad Blood,
- 0:21Speaker 1: Secrets and Lies in a Silicon Valley Startup. I could
- 0:24Speaker 1: have spoken to John for another nine hours. I found
- 0:28Speaker 1: the book absolutely fascinating. I plowed through it on Labor
- 0:31Speaker 1: Day weekend and really really enjoyed it, not just because
- 0:35Speaker 1: of how revealing it is of what turned out to
- 0:38Speaker 1: be a giant pick pick the metaphor and Ron Bertie
- 0:43Speaker 1: made off whatever, a giant fraud, but it reads like
- 0:47Speaker 1: a thriller. It's a real page turner. There are some
- 0:51Speaker 1: giant surprises throughout the book. Lots of people see their
- 0:55Speaker 1: reputation damaged and destroyed. It's amazing, and as somebody who
- 1:00Speaker 1: is also an investor, I can't help but notice how
- 1:04Speaker 1: many times there's red flag after red flag after red
- 1:07Speaker 1: flag that are excused, rationalized, ignored, somehow put shunted aside,
- 1:14Speaker 1: instead of hey, that's a big, big red flag. Maybe
- 1:17Speaker 1: we shouldn't put a billion dollars into this nonsensical company
- 1:22Speaker 1: that doesn't do any of the things it promises it
- 1:25Speaker 1: can do. Anyway, I highly recommend the book. Whether you've
- 1:29Speaker 1: read the book or not, you're gonna find this conversation fascinating. So,
- 1:33Speaker 1: with no further ado, my conversation with John carry Rout.
- 1:41Speaker 1: My extra special guest this week is John Carrrew. He
- 1:45Speaker 1: began his career in journalism in after he graduated from Duke,
- 1:52Speaker 1: he joined the Dow Jones Newswires. Shortly after, he moved
- 1:56Speaker 1: to European version of the Wall Street Journal in Brussels,
- 1:59Speaker 1: event a sually going to Paris to cover French business, terrorism,
- 2:03Speaker 1: and everything in between. He was appointed deputy Bureau chief
- 2:07Speaker 1: for Southern Europe and OH three. Eventually he became the
- 2:11Speaker 1: Wall Street Journals Health and Science Bureau chief in New York.
- 2:15Speaker 1: He has won numerous awards in journalism, including the Pulitzer
- 2:20Speaker 1: Prize twice. If this sounds like the perfect background for
- 2:23Speaker 1: any writer curious about the blood testing start up, there no, nos, Well,
- 2:28Speaker 1: it turned out that is exactly right. Uh. The Unicorn
- 2:32Speaker 1: turned out to be a fraud, which was broken by
- 2:34Speaker 1: Carrirew in the pages of the Wall Street Journal. He
- 2:37Speaker 1: has written a best selling book, Bad Blood, Secrets and
- 2:42Speaker 1: Lies in Silicon Valley about the entire Elizabeth Holmes and
- 2:46Speaker 1: thearaph O saga. John Carrirew, Welcome to Bloomberg. Thank you
- 2:50Speaker 1: for having me my pleasure. I have to start out
- 2:53Speaker 1: by saying I love the book. It was on my
- 2:55Speaker 1: list of ten to read this summer and I just
- 2:58Speaker 1: plowed through it over Labor Day week. Again, there's so
- 3:01Speaker 1: much material to cover. It's such a fascinating story. Let's
- 3:05Speaker 1: just go back to the beginning. How does Sara nos
- 3:09Speaker 1: and Elizabeth Holmes out in Silicon Valley first come on
- 3:13Speaker 1: your radar? It was mid December two thousand fourteen, and
- 3:19Speaker 1: I was on the subway UH commuting back from UH
- 3:24Speaker 1: my office in Midtown Manhattan to Brooklyn where I live,
- 3:27Speaker 1: reading the New Yorker magazine, and in that issue was
- 3:31Speaker 1: a long profile of Elizabeth Holmes by Ken all Letta
- 3:35Speaker 1: and um, it was a color glowing It was mostly
- 3:40Speaker 1: mostly glowing, with some, I have to say, with some
- 3:42Speaker 1: skeptical passages that I immediately picked up on, and UM,
- 3:47Speaker 1: you know that it was. It was an entertaining read
- 3:50Speaker 1: and interesting that there were, as I just said some
- 3:53Speaker 1: some things that struck me as odd in that story. UM.
- 3:58Speaker 1: One of the ways she she described, you know, how
- 4:01Speaker 1: her blood testing technology work, or how she worked, how
- 4:05Speaker 1: she summed it up, UH, sounded to me like a
- 4:07Speaker 1: high school chemistry student as opposed to sophisticated you know
- 4:12Speaker 1: lab scientists slash inventor um. But more than any particular thing,
- 4:17Speaker 1: it was this notion that a college dropout, someone who
- 4:21Speaker 1: had had two semesters of chemical engineering, had dropped out
- 4:26Speaker 1: and then gone on and invented groundbreaking new science that
- 4:30Speaker 1: was going to revolutionize you know, lab testing. So let
- 4:34Speaker 1: me jump in right here. So she goes to Stanford, finishes,
- 4:38Speaker 1: drops out after her freshman year. She's got no medical training,
- 4:41Speaker 1: she's got no organic chemistry, biology, um, blood chemistry, none
- 4:46Speaker 1: of the things one would normally think would go into
- 4:50Speaker 1: complex medical device manufacturing. This isn't a software startup where
- 4:55Speaker 1: you could just hey, anybody could code, and whether you
- 4:58Speaker 1: have the academic credentials or not as irrelevant. This is
- 5:01Speaker 1: a serious science, isn't it right. She she had zero qualifications.
- 5:06Speaker 1: I mean she had had literally had two undergraduate UH
- 5:12Speaker 1: courses with the same professor Channing Robertson, who ended up
- 5:15Speaker 1: being you know, her first enabler. Uh, that's an interesting
- 5:19Speaker 1: choice of words. Why did you select enabler? Well, so
- 5:23Speaker 1: he was for those listening who aren't familiar with him,
- 5:26Speaker 1: Channing Robertson was a star, rock star star of this
- 5:30Speaker 1: of the Stanford Engineering School faculty. Had been an expert
- 5:34Speaker 1: witness in the late nineties for the state of Minnesota
- 5:37Speaker 1: and its tobacco litigation, and um, you know, also was
- 5:42Speaker 1: really popular with students. He had a way with students,
- 5:44Speaker 1: he connected with them, and um, she had taken to
- 5:48Speaker 1: two courses with him, and then you know, came back
- 5:51Speaker 1: with this cockamami patent in UM after her her summer
- 5:56Speaker 1: in Singapore working at a lab in Singapore. Uh. So
- 6:00Speaker 1: we're now in in the fall of two thousand three,
- 6:03Speaker 1: and the patent was for this device that she envisioned,
- 6:07Speaker 1: which was essentially a wrist band that would have micro
- 6:10Speaker 1: needles that would come out and insert themselves into your
- 6:15Speaker 1: wrist and draw micro amounts of blood and and then
- 6:20Speaker 1: uh diagnosed whatever ailed you and cure you simultaneously. Um.
- 6:26Speaker 1: And it was clear, I mean, this was science fiction
- 6:28Speaker 1: to anyone involved an engineer or a lab scientist clear
- 6:32Speaker 1: that it was not feasible and probably ever feasible, at
- 6:36Speaker 1: least not for for decades. And uh you know, he
- 6:40Speaker 1: he chose to um go along with it and and
- 6:45Speaker 1: encouraged her to drop out, or at least didn't discourage
- 6:48Speaker 1: her to drop out, and then accompanied her on pitches
- 6:51Speaker 1: to vcs and so he gave her credibility. At that point,
- 6:54Speaker 1: she's nineteen years old, um, and he's the star of
- 6:57Speaker 1: the Stanford faculty. And then he joins the board and
- 7:00Speaker 1: he stays on there with her, accompanies her for the
- 7:03Speaker 1: next twelve years. Uh you know, he is for sure
- 7:06Speaker 1: her her original enabler. So one of the questions I
- 7:10Speaker 1: was going to ask you, but you kind of hinted
- 7:12Speaker 1: at the answer. Ready, you know, when did you first
- 7:15Speaker 1: start to smell that something was amiss? But it's pretty
- 7:19Speaker 1: clear you're you're saying right from the beginning, Well, this
- 7:22Speaker 1: struck you as a little off, Yes, But to be honest,
- 7:27Speaker 1: I probably would not have done anything with my intuition
- 7:31Speaker 1: had I not gotten approached by his source, who was
- 7:35Speaker 1: a pathologist in the Midwest who had gotten to know
- 7:39Speaker 1: the year before he moonlighted as the writer of this
- 7:42Speaker 1: obscure blog called Pathology Blog, which he spelled b L
- 7:46Speaker 1: A w G. And I had gotten him a year
- 7:49Speaker 1: prior to explain to me some of the complexities of
- 7:52Speaker 1: lab billing for a series on Medicare Medicare fraud had
- 7:55Speaker 1: been doing at the time. And he had read the
- 7:57Speaker 1: New Yorker story about Elizabeth Holmes too, and had immediately
- 8:02Speaker 1: been dubious even more than me. Uh in that you know,
- 8:05Speaker 1: he was much more familiar with with the intricacies of
- 8:08Speaker 1: lab science than I was. And he wrote a skeptical
- 8:13Speaker 1: item on his block. And uh, this guy named Richard Fuse,
- 8:20Speaker 1: who's a pretty big character in my book, by the way,
- 8:23Speaker 1: had been a childhood neighbor of Elizabeth and her parents
- 8:27Speaker 1: immediately got in touch with the Pathology blogger and told him,
- 8:31Speaker 1: you're on the right track. I think the areness as
- 8:34Speaker 1: a scam. You should keep digging into this. And Fuse
- 8:38Speaker 1: had been involved in litigation with Elizabeth Holmes. He had
- 8:42Speaker 1: patented a part of her vision that had caused her
- 8:47Speaker 1: to sue him, and she had steamrolled him with David Boys.
- 8:52Speaker 1: David Boys had become her attorney and thereness attorney, and
- 8:55Speaker 1: and they really steamrolled Fuse in this litigation, and during
- 8:59Speaker 1: the course of the lime atient, Fuse had become convinced,
- 9:02Speaker 1: as a actually trained doctor and medical inventor that thereon
- 9:06Speaker 1: us was a scam. Hold that thought, we're gonna come
- 9:08Speaker 1: back to that. Let's talk about some of those secrets
- 9:11Speaker 1: and lies. The question that I still haven't come to
- 9:17Speaker 1: a solid answer was simply this with was this a
- 9:21Speaker 1: scam from day one or did this eventually morph into
- 9:26Speaker 1: a scam? What it was the latter it wasn't a
- 9:29Speaker 1: scam from day one, and that she didn't drop out
- 9:32Speaker 1: of Stanford at nineteen and late two thousand three premeditating
- 9:37Speaker 1: a long con that would defraud investors and eventually put
- 9:41Speaker 1: patients in harm's way. That that was not in her
- 9:44Speaker 1: thoughts back then. Even though she's never spoken to me, um,
- 9:48Speaker 1: I know that she dropped out wanting to become a
- 9:52Speaker 1: successful Silicon Valley entrepreneur. Her idol was Steve Jobs. She
- 9:56Speaker 1: worshiped Apple and she wanted to follow in his footsteps.
- 10:01Speaker 1: And she also had this, you know, this notion that
- 10:04Speaker 1: she should do good for society because her her father
- 10:08Speaker 1: had worked at the State Department and various other government
- 10:12Speaker 1: agencies and and uh provided um, you know, help and
- 10:16Speaker 1: and disaster torn areas, and there were photos of him
- 10:19Speaker 1: and and he had raised her, uh with this notion
- 10:22Speaker 1: that she should live a life of purpose and and
- 10:25Speaker 1: that she should make her mark and not just by
- 10:28Speaker 1: getting rich. And so biotechnology, in her mind, was was
- 10:32Speaker 1: the gateway to achieving both becoming rich like her ancestors,
- 10:37Speaker 1: the Fleishman's had once been, and also doing good. And
- 10:40Speaker 1: so that's the way in which she was different from
- 10:42Speaker 1: Steve's jobs. She wanted a product that would that would
- 10:45Speaker 1: do good for society. Um. And uh, you know, so
- 10:49Speaker 1: it wasn't it wasn't a fraud. From the beginning she
- 10:52Speaker 1: had she had good intentions. It became a fraud with
- 10:56Speaker 1: the years as she confronted uh, you know, failures and difficulties.
- 11:03Speaker 1: Because science is hard. Medicine is hard. Science is hard.
- 11:06Speaker 1: So let let me ask you about that. A number
- 11:09Speaker 1: of people that you write about in the book point
- 11:12Speaker 1: out that the reason we do venus drawing, the reason
- 11:15Speaker 1: we take blood from your arm and fill three big
- 11:18Speaker 1: vials is that's a clean sample of blood. When you
- 11:22Speaker 1: do a pin prick, you're damaging tissue. Even if you
- 11:25Speaker 1: clean the surface of the skin. It's not as clean
- 11:28Speaker 1: a sample of of blood. So it makes makes me
- 11:32Speaker 1: raise the question, isn't it kind of reckless to say, oh,
- 11:35Speaker 1: I could you know, I could run into medicine and
- 11:38Speaker 1: figure this out despite lacking a background. I mean, it's
- 11:42Speaker 1: hubris and arrogance. It's incredibly naive to think that people
- 11:47Speaker 1: hadn't tried capillary blood draws. They had, and and one
- 11:52Speaker 1: of the problems with them, The biggest problem is is
- 11:55Speaker 1: what you say, which is that the risk UH that
- 11:58Speaker 1: basically capillary drop capillary blood is not as pure as
- 12:02Speaker 1: venus blood. It's polluted by tissue from cells and and
- 12:07Speaker 1: from skin, and UH that that stuff interferes with the
- 12:12Speaker 1: blood tests and so UH one of the biggest problems
- 12:17Speaker 1: when you try to do a blood test. UH, the
- 12:20Speaker 1: biggest problem is the potassium blood test, because what happens
- 12:23Speaker 1: is when you milk blood from the finger, you cause
- 12:29Speaker 1: the red blood cells in the blood to burst, and
- 12:33Speaker 1: the bursting UH causes a release of potassium, and so
- 12:36Speaker 1: it increases the concentration of potassium in your sample. And
- 12:41Speaker 1: and the concentration of potassium becomes artificially high, and that
- 12:45Speaker 1: little blood sample and In fact, that is one of
- 12:48Speaker 1: the problems that UH the ants ran into when it
- 12:52Speaker 1: started going live with its blood tests and Walgreen stores
- 12:54Speaker 1: in late two thou thirteen, was this hemolysis problem. And
- 12:58Speaker 1: this is in hindsight bias that was well known for decades.
- 13:01Speaker 1: This is not a new discovery, right, I mean, the
- 13:06Speaker 1: problems with capillary blood draws were well known among lab
- 13:09Speaker 1: scientists for sure. And then there's another problem that you
- 13:13Speaker 1: haven't talked about, which doesn't have to do necessarily with
- 13:15Speaker 1: the fact that it was blood pricked from the finger
- 13:18Speaker 1: that her vision revolved around. It's it's the how small
- 13:21Speaker 1: the sample was. She she wanted, you know, to be
- 13:24Speaker 1: able to do hundreds of tests from a drop or
- 13:26Speaker 1: two of blood, and no one had figured out how
- 13:30Speaker 1: to do that many tests from that small sample. The
- 13:34Speaker 1: basic reason is that there are about half half a
- 13:37Speaker 1: dozen big classes of blood tests, and each one of
- 13:41Speaker 1: these classes blood tests requires completely different laboratory techniques and
- 13:46Speaker 1: laboratory instruments. And so once you've done a couple of
- 13:49Speaker 1: blood tests that are saying immuno assays, and you try
- 13:54Speaker 1: to do blood tests from a different category, such as
- 13:58Speaker 1: general assays or hematasergy tests. You no longer have any
- 14:01Speaker 1: blood left because you've used your small sample to do
- 14:06Speaker 1: the test, and then you need more blood because the
- 14:09Speaker 1: other tests required completely different methods and completely different instruments.
- 14:12Speaker 1: And so no one had been able to crack that nut.
- 14:15Speaker 1: They've been trying to do so for more than two
- 14:17Speaker 1: decades an industry and uh in universities, and she came
- 14:21Speaker 1: along and claimed that she had solved all these problems,
- 14:24Speaker 1: even though she hadn't solved a single one of these problems.
- 14:27Speaker 1: She just stated her intention to solve them, and money
- 14:30Speaker 1: flowed in. Is that is that a fair? Well? She not,
- 14:33Speaker 1: I mean it's not quite. I mean that that would
- 14:36Speaker 1: that would be more accurate than what she did. Had
- 14:38Speaker 1: had she stated her intention to solve them, she asserted
- 14:43Speaker 1: that she had solved them. She said, I have solved
- 14:46Speaker 1: this nut that no one on earth has solved until now.
- 14:50Speaker 1: I have cracked it. And it was it was completely untrue.
- 14:54Speaker 1: So back to the question about not a fraud From
- 14:58Speaker 1: the beginning, when did it become clear that none of
- 15:03Speaker 1: their products worked? And they started lying to partners, potential investors,
- 15:09Speaker 1: even employees that hey, we we got a dead parrot
- 15:13Speaker 1: on our hands here right, So the lying actually started
- 15:16Speaker 1: very early on. I mean the book opens the prologue
- 15:20Speaker 1: is a scene that takes place in late two thousand
- 15:22Speaker 1: and six, and it's the CFO, the chief financial officer
- 15:25Speaker 1: if there on us at the time, learning that these
- 15:27Speaker 1: demos that he's bringing, he's been bringing perspective investors around
- 15:32Speaker 1: four for about eight months, are not really real. There's
- 15:37Speaker 1: a fake machine, it spits out a fake piece of paper. Right.
- 15:40Speaker 1: Part of the demo is real, the micro fluid ix
- 15:42Speaker 1: part of the demo is real, but then the result
- 15:44Speaker 1: at the end as a prerecorded results, so it's essentially
- 15:47Speaker 1: not the result from the blood that you see flowing
- 15:49Speaker 1: through the cartridge. And so he goes to her and
- 15:51Speaker 1: he says, you know, we can't keep doing this. The
- 15:54Speaker 1: investors I'm bringing around are under the impression that this
- 15:56Speaker 1: is totally real, and it's not. It's half fake. So
- 16:00Speaker 1: you know, that's essentially securities fraud. That's lying to investors.
- 16:02Speaker 1: We have to stop. And she turns ice cold and
- 16:05Speaker 1: says to him, you know you're not a team player.
- 16:08Speaker 1: I think you should leave right now. And it's very
- 16:12Speaker 1: clear from her demeanor and from her tone of voice
- 16:14Speaker 1: that she doesn't just mean leave leave her office, she
- 16:16Speaker 1: means leave the company. And he's just been fired, and
- 16:19Speaker 1: and so the the the unethical behavior, and the line
- 16:24Speaker 1: goes back as far as easily two thousand six, meaning
- 16:28Speaker 1: you know, less than two years into the life of
- 16:30Speaker 1: the company. And just to to elaborate a little bit
- 16:33Speaker 1: the technology, there were three iterations of the technology. There
- 16:37Speaker 1: was a real attempt at micro using micro fluid ix,
- 16:40Speaker 1: which is uh the repurposing of the micro fabrication techniques
- 16:44Speaker 1: that the computer computer chip industry pioneered. Lab scientists realized
- 16:49Speaker 1: they could use those microfabrication techniques to create tiny channels
- 16:53Speaker 1: through which you could put minute amounts of liquids. She
- 16:56Speaker 1: she made a real effort in the early years of
- 16:58Speaker 1: her company at doing a my micro fluidic device and
- 17:02Speaker 1: hit a wall. They just needed many more years, and
- 17:05Speaker 1: she didn't have the patients, and she was probably under
- 17:07Speaker 1: pressure from investors, and so they stopped that effort about
- 17:11Speaker 1: a year after that scene where she fires the CFO
- 17:14Speaker 1: and pivoted to the second iteration of the technology, which
- 17:17Speaker 1: was a converted glue dispensing robot. It was it was
- 17:21Speaker 1: a glue dispensing robot that a Theranos engineer had had
- 17:24Speaker 1: purchased from a company called piston Or in New Jersey
- 17:26Speaker 1: and essentially repurposed to be a blood testing machine. He
- 17:30Speaker 1: affixed a pipette to the robotic arm which had three
- 17:33Speaker 1: degrees of motion, and then he reprogrammed it to to
- 17:38Speaker 1: mimic what a lab scientist would do to test blood
- 17:41Speaker 1: at the bench. And she disguised it with the sleek
- 17:44Speaker 1: black and white case that she got a well known
- 17:48Speaker 1: industrial engineer to design, and that was called She called
- 17:51Speaker 1: it the Edison, named it after Thomas Edison, and um
- 17:55Speaker 1: the instrumentation basically the techniques of the editor and were
- 18:00Speaker 1: there was nothing new. It was something you know, uh
- 18:04Speaker 1: kemmy Luminescent immuno essays was a lab testing technique that
- 18:09Speaker 1: had been pioneered in the early eighties and that was
- 18:11Speaker 1: what the Edison did. And the third generation so the
- 18:15Speaker 1: Edison could only do immuno essays, which are this one
- 18:17Speaker 1: class of blood test. And of course, you know, she
- 18:21Speaker 1: wanted something because she was beginning to claim that she
- 18:23Speaker 1: had something that could do all the blood tests, so
- 18:26Speaker 1: she needed a machine that could do more than just
- 18:28Speaker 1: one class of blood tests. So the work on what
- 18:30Speaker 1: she called the Mini Lab, began in late two thousand ten,
- 18:33Speaker 1: and that work, you know, continued until recently. Um and
- 18:38Speaker 1: they've never gotten the mini lab to work. It's it's
- 18:40Speaker 1: a bigger machine than the Edison, and it's an attempt
- 18:43Speaker 1: to miniaturize all these laboratory instruments that are used to
- 18:46Speaker 1: do these different classes of blood tests. And they've not
- 18:49Speaker 1: never gotten it to work. What about the commercial stuff?
- 18:52Speaker 1: They were buying the commercial machines and then deluding the
- 18:56Speaker 1: full blood samp And so that became necessary because think
- 19:00Speaker 1: normal people if they haven't gotten their device to work
- 19:04Speaker 1: yet or will wait until they get it to work
- 19:07Speaker 1: to commercialize it. Right when you agree that that most
- 19:10Speaker 1: most people would do that, especially especially in the realm
- 19:13Speaker 1: of medicine where where your product actually you know, has
- 19:16Speaker 1: an impact on people's lives. Well, she didn't do that.
- 19:19Speaker 1: She went live with her vaunted fingerstick blood tests in
- 19:24Speaker 1: the fall of two thirteen in Walgreen stores in northern
- 19:28Speaker 1: California and Arizona. And because the mini Lab was just
- 19:31Speaker 1: a prototype that didn't work at the time, what she did,
- 19:34Speaker 1: what she and her boyfriend ordered Thereness employees to do,
- 19:38Speaker 1: was her boyfriend, her number two executives. They ordered people
- 19:45Speaker 1: in the lab to to hack machines made by the
- 19:48Speaker 1: German company siemens Um and UH to adapt them to
- 19:53Speaker 1: small fingerstick samples. And one of the steps that was
- 19:56Speaker 1: needed to to do this hacking was to dilute the
- 20:00Speaker 1: tiny fingerstick samples to create more volume in the cup.
- 20:03Speaker 1: Because these regular machines from from good old Seamans could
- 20:07Speaker 1: only test a normal sized sample of blood, and so
- 20:12Speaker 1: you need a lot more sample for the machine to work.
- 20:15Speaker 1: And so they diluted the fingerstick blood to create more volume,
- 20:19Speaker 1: which itself caused all sorts of problems. Let's talk a
- 20:23Speaker 1: little bit about the process that it took to get
- 20:26Speaker 1: people to speak to you, and the threats of litigation
- 20:29Speaker 1: and everything against the journal. Um. How challenging was it
- 20:34Speaker 1: to bring this story to light and ultimately to get
- 20:37Speaker 1: it in print at the Wall Street Journal? By far
- 20:41Speaker 1: the toughest story that I've ever done in twenty years,
- 20:43Speaker 1: twenty plus years of reporting. Um that the challenge was twofold.
- 20:48Speaker 1: It was getting sources to trust me and to talk
- 20:52Speaker 1: to me, Um, which was was very hard because uh,
- 20:57Speaker 1: uh Elizabeth Holmes. Uh, they knew that Elizabeth Holmes and
- 21:01Speaker 1: her company were very litigious, and they knew that the
- 21:04Speaker 1: company's outside council was was David Boys, America's premier litigated.
- 21:09Speaker 1: And and when you say litigious, not just you know,
- 21:13Speaker 1: everybody knows people who litigious. These people were seemed to
- 21:16Speaker 1: be extremely aggressive and used all sorts of questionable approaches. Right.
- 21:23Speaker 1: Elizabeth Holmes had sued former employees early on in two
- 21:26Speaker 1: as far back as two thousand seven for supposedly stealing
- 21:30Speaker 1: trade secrets. And then she had sued her childhood neighbor,
- 21:34Speaker 1: Richard Fuse, who had patented a part of her vision
- 21:38Speaker 1: um that and that infuriated her, so she came up
- 21:41Speaker 1: with a story that he and his son had had
- 21:44Speaker 1: basically colluded to steal proprietary thereinos patent information from a
- 21:50Speaker 1: law firm where where the Sun was working. But there
- 21:53Speaker 1: was never any proof whatsoever uh that that that ever happened.
- 21:57Speaker 1: And and personally, based on all my report, I believe
- 22:00Speaker 1: that it never did happen and that those were false accusations.
- 22:03Speaker 1: When you mentioned trade secrets, what trade secrets that they
- 22:07Speaker 1: had nothing? No, technically was what were there any trade secrets?
- 22:10Speaker 1: And by the way, I'm relying primarily on your book.
- 22:13Speaker 1: When I say I don't see any trade secrets here,
- 22:16Speaker 1: am I rong? No? There were There weren't really any
- 22:20Speaker 1: trade trade secrets. Was is a technical definition of that
- 22:24Speaker 1: is it was basically a way to to say, you know, a,
- 22:29Speaker 1: we can't tell you what we have because if we
- 22:31Speaker 1: tell you about it, our big competitors, Quest and lap
- 22:35Speaker 1: Corps are going to copy us um and and be uh,
- 22:39Speaker 1: you know, you all of your reporting. You have to
- 22:42Speaker 1: either destroy it or or return it to us. Uh,
- 22:47Speaker 1: you know, because it's sensitive and it could do us
- 22:49Speaker 1: great harm. These were the arguments that that Saronis and
- 22:52Speaker 1: David Boys used to try to get us to kill
- 22:55Speaker 1: my reporting and to not publish the story. Well, they
- 22:58Speaker 1: were right, it was sense of and it could do
- 23:01Speaker 1: them great harm. However, there were no It doesn't seem
- 23:05Speaker 1: like there was anything other than the bad behavior and
- 23:08Speaker 1: fraud in the company that you revealed, right, And so
- 23:12Speaker 1: it gave rise to a surreal five hour showdown at
- 23:15Speaker 1: one point in in June of two fifteen at the
- 23:18Speaker 1: journal's offices in a conference room, uh pitting me and
- 23:23Speaker 1: my editor of mix A Canolfi and and our lawyer
- 23:26Speaker 1: Jake Conty on one side of the table, and David
- 23:28Speaker 1: Boys and two of his associates, and and his former
- 23:32Speaker 1: boys Schiller partner Heather King, who had become the General
- 23:34Speaker 1: council of Theonis, And we went around in circles for
- 23:38Speaker 1: hours because um, you know, I had sent them a
- 23:41Speaker 1: list of questions ahead of time, and I was trying
- 23:43Speaker 1: to get answers to these questions, and they would say, well,
- 23:46Speaker 1: we can't answer that question because it's a trade secret,
- 23:48Speaker 1: covers trade secrets, and and of course, uh, my questions
- 23:54Speaker 1: went to the essence of weather THEONIS really had technology
- 23:57Speaker 1: and really was using proprietary technology to do it's blood
- 24:00Speaker 1: tests based on my sources, my confidential sources, it wasn't.
- 24:04Speaker 1: So I would ask things like, how many of the
- 24:08Speaker 1: blood tests on your menu are you doing right now
- 24:12Speaker 1: with para nos proprietary technology? And they would say, we
- 24:16Speaker 1: can't answer that. That's a trade secret. And I said, well,
- 24:20Speaker 1: are you and using any third party machines by the
- 24:23Speaker 1: likes of Semens to do any of these tests? We
- 24:26Speaker 1: can't answer that, that's a trade secret. And it got
- 24:29Speaker 1: to a point where I said, well, you know, how
- 24:32Speaker 1: can how can you using a third party machine made
- 24:36Speaker 1: by another company? And modifying it be a trade secret.
- 24:40Speaker 1: That's not inventing anything, that's not doing anything new. And again,
- 24:45Speaker 1: you know, we'd go around in circles. I described the
- 24:47Speaker 1: scene in the book, and I think it's chapter twenty one,
- 24:50Speaker 1: and I felt like I was watching a performance of
- 24:53Speaker 1: the theater of the absurd um And and towards the
- 24:56Speaker 1: end of that meeting, Boys let us know that that
- 24:59Speaker 1: he'll he would be sending us correspondence written correspondence. Oh,
- 25:03Speaker 1: I've gotten written a correspondence from him. Let me share
- 25:05Speaker 1: a quick story. So I write a review of the book,
- 25:08Speaker 1: and I talked about all the red flags for investors,
- 25:11Speaker 1: not really concerned so much about um the details of
- 25:18Speaker 1: the litigation. Now, I do say that some people's reputation shafferd.
- 25:22Speaker 1: I mentioned George Schultz, I mentioned David Boyce. We get
- 25:25Speaker 1: a nasty graham from Boys and his legal um firm.
- 25:30Speaker 1: And I have to tell you, I was genuinely shocked
- 25:34Speaker 1: that my opinion column based on your book, uh, generated
- 25:39Speaker 1: this intellectually disingenuous thing full of like you made all
- 25:44Speaker 1: that stuff up. I had to go through your book
- 25:46Speaker 1: page by page. This is page to seventy eight. This
- 25:49Speaker 1: is page to sixty three is a page. It was
- 25:52Speaker 1: a very bizarre experience. What was the rest of your experiences?
- 25:56Speaker 1: Like fighting boys. He's got a reputation as literally the
- 26:01Speaker 1: premier litigator in the country, right. And so after that
- 26:05Speaker 1: five hours showdown, we got a first letter that hinted
- 26:09Speaker 1: at litigation threats if we didn't immediately return or destroy
- 26:13Speaker 1: the supposed trade secrets that I had obtained through my reporting.
- 26:17Speaker 1: And then a few days later a I believe it
- 26:21Speaker 1: was a twenty six page letter that was just this
- 26:27Speaker 1: this assault on my journalistic integrity and this attempt to
- 26:31Speaker 1: portray me as a rogue reporter, that that the journal
- 26:35Speaker 1: should disown and um. And at the end of that letter,
- 26:39Speaker 1: it was very explicit that if we continued to proceed
- 26:42Speaker 1: with my reporting that the journal would be sued. And
- 26:47Speaker 1: even as these increasingly threatening letters land, um, some of
- 26:53Speaker 1: my sources start either going dark or calling me petrified
- 26:58Speaker 1: because they tell me they're being followed um and they're
- 27:01Speaker 1: being threatened as well. One of my sources, it has
- 27:04Speaker 1: since emerged, was Tyler Schultz, a young man who was
- 27:08Speaker 1: the grandson of the former Secretary of State George Schultz,
- 27:12Speaker 1: who was a member of the theraness board. Tyler is
- 27:15Speaker 1: essentially the hero of He's a hero. I wouldn't say
- 27:18Speaker 1: he's the only hero, Okay, I would I would say
- 27:20Speaker 1: another guy whom I referred to as Alan Beam in
- 27:23Speaker 1: the book, who's the ex lab director. That's a pseudonym.
- 27:27Speaker 1: I would say he's arguably the bigger hero because he
- 27:30Speaker 1: was the first to to talk to me and to
- 27:32Speaker 1: and to launch my investigation. But Tyler is absolutely a
- 27:35Speaker 1: hero in this. And Tyler had worked at the company
- 27:39Speaker 1: for eight months, become convinced during his stint there, based
- 27:43Speaker 1: on what he saw, seen and heard, that the company
- 27:46Speaker 1: was a fraud, tried to alert his grandfather, tried to
- 27:49Speaker 1: talk sense into him, hadn't been able to and then
- 27:51Speaker 1: had had had to keep that all bottled up for
- 27:54Speaker 1: a year until I came along and made contact with him,
- 27:57Speaker 1: and then he became croberating source. And after that five
- 28:00Speaker 1: hour meeting um or in fact it was, it was
- 28:03Speaker 1: a little bit before even but unbeknownst to me, uh,
- 28:07Speaker 1: two boys Schiller attorneys ambushed Tyler at his grandfather, George's
- 28:13Speaker 1: house off the Stanford campus and tried to get him
- 28:16Speaker 1: to sign documents. Essentially, uh, you know, acknowledging that he
- 28:21Speaker 1: had been a source for the journal and naming other
- 28:25Speaker 1: journal sources. And at that point began a a three
- 28:29Speaker 1: or four month campaign of threats and intimidation against Tyler Um.
- 28:34Speaker 1: He had to hire his own counsel up him. They
- 28:39Speaker 1: at one point, a a lawyer for boys Schiller named
- 28:43Speaker 1: Mike Brill, threatened to uh bankrupt Tyler Schultz's entire family
- 28:49Speaker 1: if he didn't sign the documents that Sarons wanted him
- 28:52Speaker 1: to sign. And the documents were an affidavit where he
- 28:56Speaker 1: basically acknowledged having talked to me and and and said
- 29:01Speaker 1: it was an essentially essentially a recanting of everything he
- 29:04Speaker 1: told me. And then they also wanted him to to
- 29:06Speaker 1: name my sources. And and Tyler never signed any of
- 29:09Speaker 1: these documents despite these these outrageous threats uh that were made,
- 29:15Speaker 1: and uh, you know, stood firm and in large part
- 29:17Speaker 1: thanks to him, I was able to go to print
- 29:19Speaker 1: months later with my first story which broke the scandal
- 29:22Speaker 1: open that Yet, let's continue discussing the fall. So you
- 29:29Speaker 1: have a couple of people who were insiders, Um, George
- 29:32Speaker 1: Schultz's grandson Tyler. There was a woman who worked with
- 29:36Speaker 1: him who worked in the lab. Chung who who apparently
- 29:39Speaker 1: was scared out of her mind? Right, what what happened
- 29:42Speaker 1: with her? What did she do? What was she sharing
- 29:45Speaker 1: with you? And what happened? Why? What were the intimidation attempts?
- 29:49Speaker 1: So boys and his henchmen came to the Journal's offices.
- 29:54Speaker 1: I think I believe it was on Tuesday in late June,
- 29:57Speaker 1: and that Friday, three days later, h Erica was working
- 30:01Speaker 1: at her new employer. She had left the as she
- 30:03Speaker 1: had left Aaroness in fact, the day after Tyler had
- 30:05Speaker 1: left Theariness a year prior, and she was now working
- 30:07Speaker 1: at a new company. So it's a year after she quit, right,
- 30:10Speaker 1: and she's working late at this new company, and I
- 30:13Speaker 1: think it was Sunny Veil, California, and one of her
- 30:16Speaker 1: colleagues taps around the shoulder and says, you know, there's
- 30:18Speaker 1: a man who's been waiting outside for a long time,
- 30:21Speaker 1: saying he wants to talk to you. And so her
- 30:24Speaker 1: sort of alarm bell start ringing in her head because
- 30:27Speaker 1: the the head of human resources at UH, Saraonis Uh,
- 30:31Speaker 1: this woman Mona, who was uh you know, part of
- 30:35Speaker 1: the inner circle UH with with Elizabeth Holmes and Sunny
- 30:39Speaker 1: Bowani had been trying to reach her and leaving increasingly
- 30:43Speaker 1: frantic messages that day, and so immediately Erica was on
- 30:47Speaker 1: her guards, and so she asked the colleague who had
- 30:50Speaker 1: tapped her on the shoulder, to accompany her to her
- 30:52Speaker 1: car as she left the office, which the colleague did,
- 30:56Speaker 1: and when they walked out of the building, a young
- 30:59Speaker 1: man came out of a black suv and made a
- 31:02Speaker 1: beeline toward them and handed to Erica an envelope uh
- 31:07Speaker 1: and the envelope contained a letter, very aggressive letter assigned
- 31:12Speaker 1: by David Boys, threatening to sue her for disclosing trade
- 31:15Speaker 1: secrets and giving her an ultimatum, which is that she
- 31:18Speaker 1: had to meet with him and his boy scheller associates
- 31:22Speaker 1: by a certain day and a certain time or she
- 31:24Speaker 1: would be sued. But before she even got to the letter,
- 31:27Speaker 1: what freaked her out the most was that the envelope
- 31:29Speaker 1: had her name and an addressed typed on it, and
- 31:35Speaker 1: the address was a house in East Palo Alto of
- 31:39Speaker 1: a colleague at her new company that she had been
- 31:43Speaker 1: staying at for less than two weeks. Because Erica had
- 31:46Speaker 1: planned on moving to China and so she had given
- 31:49Speaker 1: up the lease on her place in Oakland just a
- 31:53Speaker 1: couple of weeks prior, and started staying with a colleague,
- 31:56Speaker 1: basically shocking at a colleague's house. UH and niece Palo Alto,
- 32:00Speaker 1: and no one knew she was staying there except for
- 32:03Speaker 1: the colleague. Her mother didn't even know she was staying there,
- 32:06Speaker 1: so there was absolutely no way to have known this
- 32:09Speaker 1: were this was her new address without having followed her.
- 32:13Speaker 1: And so so she goes home that that evening Friday
- 32:17Speaker 1: evening petrified and stays inside this this house in East
- 32:20Speaker 1: Palo Alta with the blind closed all weekend, doesn't dare
- 32:23Speaker 1: go out. And then first thing on Monday morning, she
- 32:25Speaker 1: calls me and she's terrified, and she tells me what
- 32:29Speaker 1: has happened, And UM, I'm in my car at that point,
- 32:32Speaker 1: double parked on a street in Brooklyn, waiting for the
- 32:36Speaker 1: street sweeping truck to go by. That's one of the
- 32:39Speaker 1: better aspects of UH living in New York City. Uh,
- 32:44Speaker 1: I'm being ironic. Um, And uh so I answered the
- 32:48Speaker 1: phone and it's her and we talk and I realized
- 32:51Speaker 1: that she's right. There's no way. I try to run
- 32:53Speaker 1: through the scenarios and the permutations, there's no way anyone
- 32:56Speaker 1: could have known that was her address without having her followed.
- 33:00Speaker 1: How many people in the book felt like they were
- 33:02Speaker 1: being followed? How many participants in the book or that
- 33:05Speaker 1: you didn't might not have printed? At least three? Alan Beam,
- 33:09Speaker 1: the ex lab director Again that's a pseudonym. Uh, Tyler,
- 33:13Speaker 1: Schultz and Erica all either got word that they were
- 33:16Speaker 1: being followed or strongly suspected they were being followed, or
- 33:19Speaker 1: had evidence or had reason to believe that they were
- 33:22Speaker 1: being followed. And what about the fuses did was there
- 33:24Speaker 1: any any suspicions? Right? The Fuses had been had come
- 33:28Speaker 1: to the conclusion that they were being followed by p
- 33:31Speaker 1: I s. But that was several years prior, during the
- 33:35Speaker 1: patent litigation that had pitted them against their nos. So
- 33:39Speaker 1: something interesting that was brought up from that boys won
- 33:43Speaker 1: the patent litigation and was paid not in cash but
- 33:47Speaker 1: in pharan no stock. I was very surprised by that.
- 33:50Speaker 1: Is that common in legal circles or Silicon I know
- 33:54Speaker 1: in Silicon Valley it's not unusual, but in patent litigation
- 33:59Speaker 1: how how common or common is that? I mean, I
- 34:01Speaker 1: don't think it's very common. Um and uh for me
- 34:06Speaker 1: when I learned about it. I learned about it. I
- 34:09Speaker 1: think it was in the in the winter of two
- 34:12Speaker 1: thousand sixteen, a couple of months after my first story
- 34:15Speaker 1: was published. I thought it was a huge conflict of
- 34:17Speaker 1: interest because here you had a lawyer and his law
- 34:21Speaker 1: firm that owned almost five million shares, you know, a
- 34:26Speaker 1: five million dollars worth of shares UM, and so he
- 34:31Speaker 1: was no longer just the legal advocate of Pharaos. He
- 34:36Speaker 1: also um had skin in the game financially, and I
- 34:41Speaker 1: felt self interest, not mere advocacy on behalf of client,
- 34:44Speaker 1: and and uh, you know, I I strongly felt that
- 34:47Speaker 1: that was a conflict of interest. And I wonder if
- 34:51Speaker 1: that I wonder if that clouds a lawyer's judgment in
- 34:53Speaker 1: some of the things you described, if people do that
- 34:57Speaker 1: when they're representing clients as opposed to I don't see.
- 35:00Speaker 1: I don't see how can they can say that it
- 35:01Speaker 1: doesn't And I don't see how it doesn't it it
- 35:04Speaker 1: has to. I mean, you're you're protecting a pile of
- 35:09Speaker 1: five million dollars that, by the way, you accepted in
- 35:13Speaker 1: lieu of of regular compensation because you expected that pile
- 35:16Speaker 1: to grow as the stock and the evaluation of the
- 35:19Speaker 1: company grew to to hear them if they come out
- 35:22Speaker 1: and say so, um, you know, say that that this
- 35:26Speaker 1: didn't influence how they behaved and and and how they
- 35:30Speaker 1: worked for Thearonis, I think I would maintain as hawkwash.
- 35:33Speaker 1: So here let's talk to put some flesh on on
- 35:36Speaker 1: the bones about the dollar value of Tharonis and what
- 35:40Speaker 1: people why people thought it could go to the moon?
- 35:43Speaker 1: Um at its peak, what was the most of the
- 35:46Speaker 1: company was worth ten billion dollars? And how much money
- 35:50Speaker 1: had investors put into it. So if you count the
- 35:53Speaker 1: the money that was loaned by the private equity firm
- 35:57Speaker 1: Fortress Investment Group eight last year to keep their US afloat,
- 36:01Speaker 1: that was million dollars. If you count that cash injection,
- 36:06Speaker 1: almost a billion dollars. And so that's a you immediately
- 36:10Speaker 1: you're talking about a ten x return if it if
- 36:13Speaker 1: it keeps going. The thing that keeps coming up as
- 36:17Speaker 1: I was working my way through the book was there's
- 36:20Speaker 1: no there there there's there's really there was this initial
- 36:23Speaker 1: idea and then there was no new science developed, There
- 36:27Speaker 1: was no new technology developed. It was shocking. At what
- 36:32Speaker 1: point did the outside world before your columns start to think, hey,
- 36:38Speaker 1: there's a fraud here. Where where did the red flags
- 36:41Speaker 1: start appearing outside of the John Carrrews, No, there were
- 36:47Speaker 1: grumblings among people in the laboratory science profession. In fact,
- 36:53Speaker 1: one of the early voices was a guy at Stanford
- 36:58Speaker 1: UM UH John Ionitus UH Laboratory UH Medicine UM professor
- 37:06Speaker 1: at at Stanford. And in fact, he and I recently
- 37:08Speaker 1: had a test the exchange by email because he was
- 37:11Speaker 1: angry that I hadn't mentioned him in my book um
- 37:15Speaker 1: and and I told him that that I apologize for
- 37:18Speaker 1: the omission, but I said, at the same time, you
- 37:20Speaker 1: know he he had essentially written an opinion piece in
- 37:24Speaker 1: the journal of the Association for the American Medicine Medical
- 37:30Speaker 1: Association JAMMA UM and I believe it was in February
- 37:34Speaker 1: or March of two thousand fifteen. Um and I had
- 37:38Speaker 1: become aware of it about a month into my reporting
- 37:40Speaker 1: on the company. And really what he does in this
- 37:43Speaker 1: piece is is UH he raises the question of whether
- 37:46Speaker 1: theariness should be allowed to do what he termed stealth
- 37:50Speaker 1: research UH and and UH and he posed hard questions
- 37:55Speaker 1: about UH this trend toward companies in Silicon Valley Uh,
- 38:00Speaker 1: bypassing the traditional system of peer reviewed publication, which was
- 38:06Speaker 1: totally valid. And and you know, he put his finger
- 38:09Speaker 1: on something. But what I did respond to him was,
- 38:13Speaker 1: you know, it's one thing to raise some of these questions,
- 38:15Speaker 1: another thing to prove that the company was a fraud.
- 38:18Speaker 1: And I think he he could agree that. Um that
- 38:21Speaker 1: you know, I did the heavy lifting to to to
- 38:23Speaker 1: prove that. The two biggest red flags that leapt out
- 38:26Speaker 1: to me from the book the initial board of directors
- 38:29Speaker 1: nobody from medicine, blood sciences lab. It's all, it's two
- 38:34Speaker 1: Secretary of States, it's people from the defense. But it's
- 38:38Speaker 1: like a run of crazy things. Nobody from medicine, right, Um.
- 38:42Speaker 1: And eventually they had somebody years later. But there were
- 38:45Speaker 1: there were two out of I think twelve old men,
- 38:48Speaker 1: old white men on the board. Uh. There were two
- 38:52Speaker 1: had some connection to medicine. One was Bill Frist, who
- 38:55Speaker 1: had once been a transplant surgeon before becoming a politician.
- 38:59Speaker 1: Not from the beginning, right, wasn't he a later addition? No? No, no,
- 39:01Speaker 1: he was there from the beginning. Not from the beginning.
- 39:04Speaker 1: But the board changed over the years, and the last
- 39:07Speaker 1: iteration of the board essentially dated back to uh two
- 39:10Speaker 1: thousand eleven, two thousand twelve, so almost a decade after
- 39:14Speaker 1: they started. It's like she she acquired this new board
- 39:19Speaker 1: UM because she felt that it would help her. It
- 39:23Speaker 1: was sort of an exercise and reputational laundering, you know.
- 39:27Speaker 1: She attracted these larger than life figures with fantastic resumes.
- 39:30Speaker 1: And then the other thing that was a giant red
- 39:32Speaker 1: flag was all of the healthcare, medical sciences, medical device
- 39:37Speaker 1: venture capitalists. Every one of them took a pass. Not
- 39:41Speaker 1: a one put any money in this right because either
- 39:43Speaker 1: because either she wouldn't meet with them or when she
- 39:46Speaker 1: did accept meetings, and and some of these people started
- 39:50Speaker 1: asking hard questions. UM, her interest in continuing to meet uh,
- 39:56Speaker 1: you know, waned and and basically evaporated. We're speaking to
- 40:00Speaker 1: John Carrirew. He is the author of Bad Blood, Secrets
- 40:03Speaker 1: and Lies in a Silicon Valley Startup. If you enjoy
- 40:07Speaker 1: this conversation, well be sure and come back for the
- 40:09Speaker 1: podcast Astras, where we keep the tape rolling and continue
- 40:13Speaker 1: to discuss all things fraudulent at saranos. You can find
- 40:18Speaker 1: that wherever your final podcasts are sold Apple, iTunes, Stitcher, Overcast,
- 40:23Speaker 1: and of course Bloomberg dot com. Be sure and check
- 40:26Speaker 1: out my daily column. You can find that on Bloomberg
- 40:28Speaker 1: dot com. Follow me on Twitter at Rich Halts. I'm
- 40:31Speaker 1: Barry Rihults. You're listening to Masters in Business on Bloomberg Radio.
- 40:49Speaker 1: Welcome to the podcast, John, Thank you so much for
- 40:51Speaker 1: doing this. I have to tell you I really enjoyed
- 40:55Speaker 1: reading the book. It retreats like a thriller as you're
- 40:59Speaker 1: going through it. It's just what that that's just astounding.
- 41:04Speaker 1: It's mind blowing. Um. I'll come back to some of
- 41:07Speaker 1: the red flags. I have a ton of other questions,
- 41:10Speaker 1: but I have to ask you how much fun was
- 41:12Speaker 1: this to write? You know, it was a lot of fun.
- 41:16Speaker 1: It was the most fulfilling thing I've ever done in
- 41:19Speaker 1: my life, uh, professionally or or probably otherwise. Um, it
- 41:24Speaker 1: was nerve racking at the very beginning because you know,
- 41:28Speaker 1: I had a book deal and a movie deal to wait.
- 41:32Speaker 1: When did the movie deal before the book was written? Right?
- 41:35Speaker 1: Because the I reached my deal with Knopp to do
- 41:38Speaker 1: the book, I think it was in March, uh late
- 41:41Speaker 1: March of two thousand sixteen, and then the movie deal
- 41:43Speaker 1: came less than three months later, and I only went
- 41:46Speaker 1: on book leave and started writing the book and around
- 41:48Speaker 1: October of two thousand sixteen. So I had this pressure
- 41:53Speaker 1: from these two deals and from the fact that I
- 41:55Speaker 1: had never written a book before. And uh, you know
- 41:58Speaker 1: that's easy. You just keep going. You've had a column,
- 42:00Speaker 1: but you don't stop till you got a hundred words. Yeah.
- 42:03Speaker 1: So anyways, it wasn't easy staring at a blank word
- 42:07Speaker 1: document at first. But once I got a couple of
- 42:09Speaker 1: chapters in UM and I got the I felt like
- 42:12Speaker 1: I was in a rhythm and I was immersed. Uh.
- 42:14Speaker 1: And by the way, I was continuing to do a
- 42:16Speaker 1: lot of reporting, because the first three quarters of the
- 42:18Speaker 1: book are told in the third person and or the
- 42:22Speaker 1: what happens at the company until I come along, and
- 42:24Speaker 1: I had to re report a lot of that. Uh.
- 42:27Speaker 1: Tons of new material came out of that reporting process.
- 42:30Speaker 1: So I was really reporting and writing at the same time.
- 42:33Speaker 1: And it was just uh so fun and fulfilling. And
- 42:39Speaker 1: and I'm glad that to hear you say that it
- 42:41Speaker 1: read like a thriller, because I tried to to make
- 42:43Speaker 1: it read, uh like a page turner. I'm I'm a
- 42:47Speaker 1: big fan of Agatha Christie and UM Uh you know,
- 42:52Speaker 1: I I also uh read people like Michael Crichton and
- 42:56Speaker 1: and Dan Brown, um, and uh you know, I've picked
- 43:00Speaker 1: up on some of their some of their techniques to
- 43:03Speaker 1: to to keep the reader interested, and I channeled some
- 43:06Speaker 1: of that as I was writing this book, no doubt
- 43:07Speaker 1: about it. The um I got more questions I want
- 43:10Speaker 1: to circle back to, but I have to get into
- 43:15Speaker 1: the whole back and forth with the Wall Street Journals
- 43:18Speaker 1: editors and the threats of litigation and then the last
- 43:22Speaker 1: minute hail Mary Elizabeth Holmes polled with Rupert Murdoch of
- 43:26Speaker 1: all of old people, who who owns the Wall Street Journal.
- 43:29Speaker 1: So so let's talk a little about that. Your editors
- 43:32Speaker 1: sound like they're great. They seemed really stand up and
- 43:36Speaker 1: there was never any Carrie, what the hell are you
- 43:39Speaker 1: doing to us? You're gonna get a suit? Come on,
- 43:41Speaker 1: this is crazy. Tell us what the process was like
- 43:44Speaker 1: in the newsroom. Right. So my editor is a guy
- 43:47Speaker 1: named Mike Sikonolfi, who who's been old school, right, Yeah,
- 43:51Speaker 1: he's been at the Wall Street Journal since I think
- 43:53Speaker 1: the eighteen hundreds. I'm kidding, I didn't start till the
- 43:58Speaker 1: can't tease him a lot about how long he's been
- 44:01Speaker 1: at the journal. I think he actually joined the Wall
- 44:02Speaker 1: stret Journal in nur UM. But he's a legend at
- 44:06Speaker 1: the journal, and he is loved and admired UM. And
- 44:10Speaker 1: it's for good reason. He's a real journalist. UH loves
- 44:16Speaker 1: to do hard hitting stories and to back reporters who
- 44:20Speaker 1: are onto hard hitting stories. UM. And he's also great
- 44:24Speaker 1: in the sense that he knows, uh to to let
- 44:28Speaker 1: you have a long leash and to follow your knows.
- 44:31Speaker 1: He doesn't try to micromanage you. And UH, early in
- 44:35Speaker 1: two thousand fifteen, I think it was February one or
- 44:37Speaker 1: second week, I had gotten the tip from the pathology
- 44:41Speaker 1: blogger UH, coming on top of the New Yorker story
- 44:44Speaker 1: that had raised questions in my mind. I went to
- 44:46Speaker 1: Mike and I said, I think potentially there's a story here,
- 44:50Speaker 1: and I think potentially it could be a really sexy,
- 44:52Speaker 1: big story. And he sort of listened to me summarize, UM,
- 44:56Speaker 1: what I thought the story might be, and he was like, ahead,
- 45:00Speaker 1: you know, try it for a couple of weeks, and
- 45:02Speaker 1: then just give me an update in a couple of weeks.
- 45:05Speaker 1: And and and that's how the process started. And and UH,
- 45:07Speaker 1: you know, When I gave him the next update, it
- 45:09Speaker 1: was probably two or three weeks later, and I hadn't
- 45:11Speaker 1: made uh some headway, and so then he was like,
- 45:14Speaker 1: well keep going, and uh yeah, so he's a great
- 45:17Speaker 1: editor for sure. What what about when the nasty graham
- 45:20Speaker 1: start to show up? I have to tell you when
- 45:22Speaker 1: I got mine, and it's nothing like what you're my.
- 45:26Speaker 1: I wrote a book review. Someone didn't like my book review.
- 45:28Speaker 1: I got a h three page letter. But my immediate
- 45:32Speaker 1: reaction is, oh my god, I totally screwed up. What
- 45:35Speaker 1: did I do? And then I started reading through and
- 45:37Speaker 1: I'm like, wait, wait a second, that that's not that's
- 45:39Speaker 1: not true. Everything I wrote in there, you said henchman,
- 45:43Speaker 1: I used the word thug, But more or less everything
- 45:46Speaker 1: in there in my review came right for your book.
- 45:49Speaker 1: In fact, normally I don't do that. When I do,
- 45:52Speaker 1: might hear the ten books I'm gonna read this summer
- 45:54Speaker 1: or this winter. And I read a book and I'm like, oh,
- 45:56Speaker 1: that's interesting, and I put it aside, but I so
- 46:00Speaker 1: totally enjoyed the story. I'm like, there are red flags everywhere,
- 46:03Speaker 1: there are lessons for investors. I'm gonna write something like that.
- 46:07Speaker 1: Not my usual approach, and I wrote it never in
- 46:10Speaker 1: a million years expecting we're going to get a letter.
- 46:13Speaker 1: But you get the email and it shakes you. You're like,
- 46:17Speaker 1: holy cow, what did I do? And for a micro second,
- 46:20Speaker 1: it's I really I screwed the pooch. I really did
- 46:23Speaker 1: something terrible here. And then it took about ten seconds
- 46:27Speaker 1: before wait no, I literally shut the book and started
- 46:31Speaker 1: dictating on my iPhone because I was on the beach
- 46:34Speaker 1: and the Hampton's got home, wrote it up that night,
- 46:37Speaker 1: polished it the next morning. Off it went. It was
- 46:40Speaker 1: literally the book could not have been more fresh in
- 46:42Speaker 1: my mind before that, before that column. And so after
- 46:47Speaker 1: the letter came after I finally like took a deep breath,
- 46:53Speaker 1: figured out all the page citations that were being complained about.
- 46:57Speaker 1: You made the stuff up? No, I didn't. It's right
- 46:59Speaker 1: from the book. Look, I stopped and I said, what
- 47:02Speaker 1: was it like when carry my nothing little book review.
- 47:07Speaker 1: You're breaking major news stories. You're breaking stories that ultimately
- 47:12Speaker 1: leads to the revealing of fraud. So we have we
- 47:16Speaker 1: haven't even talked about the SEC and the other litigation
- 47:18Speaker 1: that's going on, but you basically brought down a company
- 47:22Speaker 1: that A was a fraud. B was putting people's life
- 47:25Speaker 1: and safety at risk. If you get a false positive,
- 47:29Speaker 1: well you it scares the hell to you. But there's
- 47:31Speaker 1: no danger if you get a false negative. If they
- 47:34Speaker 1: miss something because say this thing doesn't work, people die.
- 47:38Speaker 1: So what was it like when these letters started coming in,
- 47:42Speaker 1: these nasty graham start coming in. I can't imagine the
- 47:45Speaker 1: process you went through, right, It was stressful. I mean,
- 47:50Speaker 1: some of your colleagues have interviewed me about the Book
- 47:52Speaker 1: of asked whether there was any moment where I felt
- 47:55Speaker 1: in physical danger. And I don't think there was any
- 47:58Speaker 1: moment that I felt in physical ange. I mean there
- 48:00Speaker 1: were moments when I'd come out of my apartment building
- 48:03Speaker 1: in Brooklyn and I'd look left and right to see
- 48:05Speaker 1: if I could spot anyone UH following me. Do you
- 48:09Speaker 1: think you would follow? I don't know. I don't. I
- 48:12Speaker 1: don't know the assumption as they do a full online
- 48:15Speaker 1: search if they have, if they had someone following me,
- 48:18Speaker 1: and that comes out, I will not be surprised. But
- 48:21Speaker 1: I can't say one way or another whether they did
- 48:24Speaker 1: or not. I just don't know. I didn't I didn't
- 48:27Speaker 1: feel physically threatened. My biggest source of stress was that
- 48:31Speaker 1: this scorched earth campaign to intimidate my sources and turn
- 48:36Speaker 1: them and to also intimidate the paper that it would
- 48:39Speaker 1: be fruitful and that they would succeed in destroying the
- 48:43Speaker 1: scaffolding of reporting upon which I had built this story,
- 48:46Speaker 1: and that ultimately, uh, you know, the story wouldn't come out.
- 48:50Speaker 1: That was for me, that was the big source of stress.
- 48:53Speaker 1: And I finally, you know, breathed a sigh of relief
- 48:56Speaker 1: when the story was in the paper. I think it
- 48:58Speaker 1: was October, uh, two thousand fifteen, and then I didn't
- 49:03Speaker 1: really have time to basket it very long because then
- 49:05Speaker 1: I immediately you know, on to the next one. I
- 49:08Speaker 1: was on to the to the to the first follow
- 49:10Speaker 1: up story, which we published that very night. Um, and uh,
- 49:14Speaker 1: you know, from there it was months and months of
- 49:18Speaker 1: more follow up reporting, and I think, uh, with each
- 49:22Speaker 1: week that passed and with each regulatory inspection and finding,
- 49:26Speaker 1: we were vindicated more and more until recently, you know,
- 49:29Speaker 1: the criminal charges that were filed by the Justice Department,
- 49:34Speaker 1: the wire fraud fraud charges filed against Elizabeth Holmes and
- 49:37Speaker 1: Sunny Baliwani by the Justice Department. Really, you know, we're
- 49:40Speaker 1: the ultimate of vindication that my reporting was correct and
- 49:44Speaker 1: I had been right all along. What about the state
- 49:46Speaker 1: of California. Did they do any criminal investigations and it
- 49:50Speaker 1: all took place primarily in California? Are they getting a
- 49:54Speaker 1: pass by the state. Well, if you depends. If you
- 49:58Speaker 1: count the the U. S. Attorney's Office in San Francisco
- 50:03Speaker 1: as a federal it's not stage okay. So then if
- 50:05Speaker 1: you don't count them, California did nothing, that's shocking. I mean,
- 50:11Speaker 1: this is a serious fraud. It's a billion dollars and
- 50:14Speaker 1: investor money, not counting um, not counting the Fortress stuff
- 50:19Speaker 1: after the fact. So it's almost a billion dollars and
- 50:23Speaker 1: the risk to individuals. You know, one of in the
- 50:28Speaker 1: book you describe the Paraos people and I don't remember.
- 50:31Speaker 1: I was the lawyers or others intimidating some of the
- 50:34Speaker 1: doctors who had had used that. That was Sunny Bow.
- 50:37Speaker 1: That was the number two executive the company, the president
- 50:40Speaker 1: of the company, who was the boyfriend of the founder,
- 50:43Speaker 1: secret boyfriend of the secret boyfriend of the founder. She
- 50:46Speaker 1: was hiding it from everyone, including her own board, flewed
- 50:49Speaker 1: out to Phoenix and proceeded to intimidate and threaten all
- 50:53Speaker 1: the doctors who had spoken to me on the record,
- 50:55Speaker 1: And how did they know the names of those doctors
- 50:57Speaker 1: because they had asked that we a of them information
- 51:02Speaker 1: about the doctors and patients and their blood test results
- 51:04Speaker 1: so that they could rebut them and respond to them,
- 51:07Speaker 1: which is natural. I mean we you know, you have
- 51:09Speaker 1: you have to have the the party that you're investigating
- 51:11Speaker 1: and writing about has to have the opportunity to respond.
- 51:13Speaker 1: And so we did that. And what did they do?
- 51:16Speaker 1: Rather than responding, they went and they used the information
- 51:19Speaker 1: to find the people and threaten them, and didn't one
- 51:21Speaker 1: of the doctors pretty much tell them to go jump.
- 51:23Speaker 1: I thought one of the doctors was real stand up.
- 51:25Speaker 1: In the book, there were a couple of doctors who
- 51:27Speaker 1: either refused to meet with them or or told him, uh,
- 51:31Speaker 1: you know one and one comes to mind Dr Adrian Stewart,
- 51:34Speaker 1: who who too had two colleagues who had buckled under
- 51:39Speaker 1: pressure and signed these uh statements essentially recanting what they
- 51:43Speaker 1: told me. Uh. She wasn't there when her two Stewarts,
- 51:47Speaker 1: when her two colleagues uh were presented with those statements
- 51:51Speaker 1: and chickened out, And she came back a week later
- 51:54Speaker 1: by which time I hadn't managed to reach her, and
- 51:56Speaker 1: so she was prepared to be say, which she was
- 52:00Speaker 1: as soon as she got back by Sunny Bowani, and
- 52:03Speaker 1: she stood, you know. She she refused to sign the
- 52:07Speaker 1: document that he put to her, even though he told her,
- 52:10Speaker 1: if your name appears saying anything about the Ainos in
- 52:14Speaker 1: a Wall Street Journal story, we will drag your reputation
- 52:17Speaker 1: through the mud. Nice guy. Good for her. She she's
- 52:20Speaker 1: another one of the heroes in the book. So I
- 52:24Speaker 1: have to bring up the hail Mary that Elizabeth Holmes
- 52:28Speaker 1: pulled with Rupert Murdoch, who owner of Fox News, of
- 52:32Speaker 1: which Wall Street Journal was part of all the one
- 52:35Speaker 1: way I have to correct you now it's been split
- 52:38Speaker 1: blah blah. Webster Journals part of News Corps, which is
- 52:40Speaker 1: a separate company. Fox is part of Century Fix. Right,
- 52:44Speaker 1: So this is at the time it was a single entity.
- 52:47Speaker 1: This is pre split, right, this was post split split
- 52:50Speaker 1: was really alright? So part of news Corp, an investor
- 52:56Speaker 1: in Paraos. And the day before are publication was it October?
- 53:05Speaker 1: So it's two weeks before publication. She and she had
- 53:08Speaker 1: already done this once a month or two prior, when
- 53:11Speaker 1: she had invited Murdoch to come to Theonos offices in Paloazza,
- 53:15Speaker 1: and she'd raised my story with him and told him
- 53:18Speaker 1: I had gathered all this information that was false, uh, misleading,
- 53:22Speaker 1: and that would do great damage to the company if
- 53:25Speaker 1: it was published. And she had read about that the
- 53:27Speaker 1: last one, the latter she invited him to kill it,
- 53:30Speaker 1: and he the mirrored, told her that, you know, he
- 53:33Speaker 1: trusted the journal's editors to do the right thing. I
- 53:36Speaker 1: didn't want to involve himself. And then she came again
- 53:40Speaker 1: late September, I think it was September, two weeks before
- 53:44Speaker 1: my first story was published. She met with him in
- 53:46Speaker 1: his eighth floor office in News Corp Building on fifth floor,
- 53:51Speaker 1: so three floors, three floors above me. She was there,
- 53:54Speaker 1: meeting with him one on one, raising my story with
- 53:57Speaker 1: him urgently, again hoping that he would volunteer to kill it,
- 54:02Speaker 1: and uh, he did no such thing, despite having a
- 54:06Speaker 1: hundred twenty five million reasons to do. Soon dollar investment
- 54:10Speaker 1: in the Eventually Murdoch to his credit, so the story
- 54:15Speaker 1: publishes some years later. Murdoch sells his interest back to
- 54:19Speaker 1: the company for a dollar, so he gets the tax
- 54:22Speaker 1: right off a year and a half later, approximately sells
- 54:28Speaker 1: his stake back in the company to the to the
- 54:30Speaker 1: company for a symbolic dollar, so that he can use
- 54:33Speaker 1: that huge loss to write off taxes on other earnings.
- 54:38Speaker 1: But um, there wasn't addendum to that buyback deal, which
- 54:42Speaker 1: was that if Fairness settled any litigation with Huh, an
- 54:47Speaker 1: investor who felt they had been defrauded for more than
- 54:50Speaker 1: forty million dollars, then Murdoch would be entitled to another
- 54:53Speaker 1: payment of four million dollars. And so that that he
- 54:56Speaker 1: did get that additional four million dollars later because there
- 54:59Speaker 1: no settled with the San Francisco Hedge Fund partner fund
- 55:02Speaker 1: that had invested a hundred million uh Sarrens settled with
- 55:05Speaker 1: them for forty three million in the in the spring
- 55:08Speaker 1: of two thousand seventeen, and so that entitled Murdoch to
- 55:11Speaker 1: another four million. So he got four million plus one dollar.
- 55:14Speaker 1: He's still in other words, he's still lost one million dollars. Amazing. Um,
- 55:19Speaker 1: there's a couple of other selmans. I wanted to ask
- 55:22Speaker 1: this safe way in Walgreens, these companies had such a
- 55:26Speaker 1: bad case of Foamo. They spent a ton of money
- 55:29Speaker 1: because they were afraid their competitors would get in over
- 55:33Speaker 1: them despite never seeing the machine, never getting the technology
- 55:38Speaker 1: of the science. Well, they saw the machine, but she
- 55:40Speaker 1: would do these these fake demos again. So the real
- 55:43Speaker 1: machine they saw, no, they saw, they saw the real machine.
- 55:46Speaker 1: But there was a what they called this secret demo
- 55:48Speaker 1: protocol where the Walgreens or the safe Way representative, or
- 55:52Speaker 1: sometimes the board member or even the journalist came and
- 55:56Speaker 1: had you know, saw the mini lab which was this
- 55:59Speaker 1: big black box with a digital UH interface, and they'd
- 56:04Speaker 1: have their finger pricked and the small fingerstick sample would
- 56:08Speaker 1: be put in this cartridge which itself would be slotted
- 56:10Speaker 1: into the mini lab machine. The Mini lab machine would
- 56:14Speaker 1: be turned on and the testing what you'd hear the
- 56:17Speaker 1: worrying of the machine. And so you think the testing
- 56:19Speaker 1: has started, and they'd say this is gonna take a while.
- 56:22Speaker 1: Why don't you go out for lunch or visit the
- 56:24Speaker 1: rest of the building, or meet with Elizabeth in her
- 56:27Speaker 1: office and then we'll get you your test result. And
- 56:31Speaker 1: so the person Walgreen, Safeway or board member would leave
- 56:35Speaker 1: the room and then when they were out of sight,
- 56:39Speaker 1: a THEONIS employee would stop the Theoronis Mini Lab UH
- 56:44Speaker 1: take the cartridge out, take the blood sample out of
- 56:46Speaker 1: the cartridge, and bring it to the Theonis lab where
- 56:50Speaker 1: they would either test it manually at the bench or
- 56:54Speaker 1: run it on one of the hacked Semens analyzers. So
- 56:57Speaker 1: if someone says, no, I'm fine, I got my phone,
- 56:59Speaker 1: I'm gonna just day busy, I just want to watch
- 57:01Speaker 1: this machine work, nothing would have happened. Well, they yeah,
- 57:06Speaker 1: you would have been pretty much without saying so, calling
- 57:09Speaker 1: their bluff, and I'm sure they would have come up with,
- 57:12Speaker 1: you know, some um excuse to get you out of
- 57:16Speaker 1: the room at some point so that they could pull
- 57:18Speaker 1: off their sliders cans. So this is this has been
- 57:21Speaker 1: a deep fraud from let's call it oh six oh seven.
- 57:25Speaker 1: Is that about right? Yeah? I mean you you could
- 57:27Speaker 1: argue that the fraud didn't matter as much until two
- 57:31Speaker 1: thirteen as long as the company remained in R and
- 57:33Speaker 1: D mode and never went live with the technology. Right.
- 57:38Speaker 1: But the second you commercialize the technology and you start
- 57:41Speaker 1: offering it to the public, which is what started happening
- 57:43Speaker 1: in the fall two thirteen, then it becomes a gigantic
- 57:46Speaker 1: fraud because it's not just investors who are being defrauded,
- 57:50Speaker 1: but it's the public that's being put in harm's away
- 57:53Speaker 1: and that and that's really you know, I think that's
- 57:56Speaker 1: what elevates this scandal, uh and puts it in in
- 58:00Speaker 1: antheon of of you know, modern financial scandals. Let's let's
- 58:04Speaker 1: talk about the army and Lieutenant Colonel Shoemaker, a no
- 58:08Speaker 1: nonsense guy with a medical background, was to approve all
- 58:11Speaker 1: of these um experimental R and D s. Holmes but
- 58:18Speaker 1: or whoever it was bumps into him when trying to
- 58:21Speaker 1: get this approved for the army. And this guy doesn't
- 58:24Speaker 1: take any bs, sees right through it practically from the beginning, well,
- 58:29Speaker 1: he didn't. He didn't necessarily think that the technology didn't work.
- 58:33Speaker 1: He didn't know whether it worked or not. Um, But
- 58:37Speaker 1: what he felt strongly about was that this device needed
- 58:42Speaker 1: to be approved by the FDA. It's a medical device
- 58:45Speaker 1: for testing blood. How couldn't it be right? And and
- 58:48Speaker 1: and the f d A approves all laboratory testing equipment
- 58:52Speaker 1: that laughs by and so he felt that the Thermis
- 58:55Speaker 1: device was no exception. And so what he really had
- 58:58Speaker 1: a problem with was this regular to strategy that Elizabeth
- 59:01Speaker 1: Holmes head um, you know, presented him with in in
- 59:05Speaker 1: two thousand eleven, a couple of months after she had
- 59:08Speaker 1: met Maddis and wrapped Manis around her finger and gotten
- 59:11Speaker 1: Maddis to back this notion that the Themis technology would
- 59:14Speaker 1: be used in the field in Afghanistan. And for that
- 59:17Speaker 1: to happen, it had to go through Lieutenant Colonel Shoemaker
- 59:20Speaker 1: at Fort Detrick UH in Maryland because he was the
- 59:24Speaker 1: guy who had to approve such experiments. So this lieutenant
- 59:27Speaker 1: colonel gets a phone call from a four star general,
- 59:30Speaker 1: Is that right? Right? And so yeah, later, you know,
- 59:33Speaker 1: he had has these these clash diplomatic clashes with Elizabeth
- 59:37Speaker 1: and it becomes clear, uh to her that she's not
- 59:41Speaker 1: gonna be able to steamroll him. And but so she
- 59:44Speaker 1: appeals to to Maddis and she emails him and at
- 59:48Speaker 1: that point he's actually in the war theater in Afghanistan
- 59:51Speaker 1: and uh she uh because what what's happened by then
- 59:54Speaker 1: is that Shoemaker has not only resisted what she wants
- 59:58Speaker 1: to do, he has passed on what's he what he's
- 1:00:03Speaker 1: learned about the Theoranis regulatory approach to the f d
- 1:00:05Speaker 1: A and two CMS, the Centers for Medicare and Medicaid Services,
- 1:00:09Speaker 1: and CMS has dispatched an inspector to do a surprise visit.
- 1:00:13Speaker 1: And Elizabeth is furious about this, and so she writes Madis,
- 1:00:17Speaker 1: who's an Afghanistan, and Mannis gets her email. He's furious.
- 1:00:21Speaker 1: And so in August of two thousand twelve, Shoemaker has
- 1:00:25Speaker 1: to fly down with an FDA official to Tampa, Florida,
- 1:00:30Speaker 1: which is, you know, the headquarters of the Central Command,
- 1:00:32Speaker 1: because Maddis at that point was the head of the
- 1:00:34Speaker 1: Central Command. And he has to meet with Mannis and
- 1:00:37Speaker 1: explain to this legendary journal general, I'm sorry, uh that
- 1:00:44Speaker 1: uh you know that that he can't say yes to
- 1:00:47Speaker 1: what this uh general wants uh and and here's why.
- 1:00:51Speaker 1: And so he and this um FDA official named Alberto
- 1:00:54Speaker 1: Gutierrez go in brief Maddis um and they reach a compromise,
- 1:00:59Speaker 1: which is that Theoronis can the Thearoness experiment can proceed
- 1:01:03Speaker 1: only if it's using after the fact, left over de
- 1:01:09Speaker 1: identified samples from wounded soldiers wounded or healthy for that matter,
- 1:01:14Speaker 1: and um and so that they could feed it into
- 1:01:16Speaker 1: it if they want a big sample of blood to
- 1:01:19Speaker 1: run tests. But nobody in the field is relying on
- 1:01:22Speaker 1: this for medical exactly exactly and so, but that you know,
- 1:01:25Speaker 1: that opens a window for for Theoroness to do this,
- 1:01:28Speaker 1: and inexplicably, over the ensuing months, Theonis can never seem
- 1:01:32Speaker 1: to get its act together to to get the study
- 1:01:36Speaker 1: protocol written and ready, um and and and then you know,
- 1:01:41Speaker 1: everyone retires, Mannis retires, his uh aid de camp retires,
- 1:01:47Speaker 1: Shoemaker ends up retiring mid two thirteen. Um. The live
- 1:01:51Speaker 1: experiment in the field in Afghanistan, and that Elizabeth wanted
- 1:01:55Speaker 1: never ends up happening. And then wait, wait, wait, wait
- 1:01:57Speaker 1: wait why would she want to live? Is she still
- 1:02:01Speaker 1: under the illusion this damn thing works? Like how delusional
- 1:02:05Speaker 1: is she? She thinks that it's sort of works. And
- 1:02:09Speaker 1: then in the end, just a few tweaks right that
- 1:02:12Speaker 1: you know, will iterate and uh and and basically what
- 1:02:17Speaker 1: she has her eyes on is two things. She has
- 1:02:20Speaker 1: her eyes on the potentially huge new revenue stream that
- 1:02:25Speaker 1: a contract with the Pentagon, of course would bring. And
- 1:02:29Speaker 1: she has her eyes on the validation of fairness that
- 1:02:33Speaker 1: she would get by by virtue of being a supplier
- 1:02:38Speaker 1: of this technology to the Pentagon. And what year is this?
- 1:02:41Speaker 1: This is two thoen So when did the Safe Way
- 1:02:45Speaker 1: and the Walgreens deals fall apart. So the Walgreens deal
- 1:02:49Speaker 1: only fell apart after my revelations, and it took not
- 1:02:54Speaker 1: even two sixteen. Really, I mean it fell apart in steps.
- 1:02:58Speaker 1: But they really, uh you know, ended the whole thing
- 1:03:01Speaker 1: in two thousand sixty. And I think it was the
- 1:03:03Speaker 1: summer of two thousands, just a big three hundred million
- 1:03:05Speaker 1: dollar right off or whatever it was. It was a
- 1:03:07Speaker 1: d forty million that Walreens put in therapis. But I mean,
- 1:03:10Speaker 1: but what about the renovator who did the big renovation
- 1:03:14Speaker 1: was safe Way safe Weight loaned there, no thirty million,
- 1:03:16Speaker 1: but on on the side, in addition to that loaned
- 1:03:19Speaker 1: it renovated, uh, these these clinics inside its supermarkets and
- 1:03:24Speaker 1: and about eight hundred of its supermarkets, Uh, in anticipation
- 1:03:28Speaker 1: of you know, having the Theonis technology offered there. And
- 1:03:32Speaker 1: that renovation cost three million dollars. So at least they
- 1:03:37Speaker 1: got new painting carpet is amazing. Um. The other two
- 1:03:42Speaker 1: before I get to my standard questions, the other two
- 1:03:45Speaker 1: um sort of frauds that that stood out that was surprising.
- 1:03:50Speaker 1: One was the Johns Hopkins letter the right explain the
- 1:03:56Speaker 1: faux endorsement. Right, So uh, she goes to uh, Walgreen's
- 1:04:03Speaker 1: has hired Johns Hopkins as sort of a consultant as
- 1:04:08Speaker 1: it's beginning to set up this partnership with Sanis and
- 1:04:12Speaker 1: so in I believe it's May of two thousand ten,
- 1:04:16Speaker 1: Elizabeth and her boyfriend's Sonny go to the Johns Hopkins
- 1:04:20Speaker 1: campus to meet with several Hopkins officials, among them laboratory scientists.
- 1:04:25Speaker 1: And they come with what is then the Edison, the
- 1:04:27Speaker 1: black and white device, and they come with binders full
- 1:04:31Speaker 1: of data, um, and they explain, you know, what the
- 1:04:35Speaker 1: device does, and they show these binders with these graphs
- 1:04:40Speaker 1: that show, you know, it's basically a diagonal line that
- 1:04:43Speaker 1: shows a very tight correlation between the data from the
- 1:04:47Speaker 1: Tharanis tests and regular technology with you know, regular Venus draws.
- 1:04:52Speaker 1: And that was a scam also, And that was a scam.
- 1:04:54Speaker 1: Those were fake, fake graphs and fake data. Um. But
- 1:04:58Speaker 1: they meant for a couple of hours, and you know,
- 1:05:00Speaker 1: the meeting, at theirness's request, gave rise to a two
- 1:05:04Speaker 1: page letter, not even two pages, a page and a half,
- 1:05:07Speaker 1: which was essentially a summary of the meeting, minutes from
- 1:05:09Speaker 1: the meeting, saying this meeting happened, and you know what
- 1:05:13Speaker 1: the airiness has described sounds interesting. And by the way,
- 1:05:16Speaker 1: there's like small boilerplate uh at the end of the
- 1:05:19Speaker 1: second letter saying you know, this is in no way
- 1:05:21Speaker 1: an endorsement by Johns Hopkins of any uh Thereness technology.
- 1:05:27Speaker 1: And she then uses this over the ensuing two or
- 1:05:29Speaker 1: three years to claim that UH tharoness Is technology has
- 1:05:35Speaker 1: been independently verified and validated by the Johns Hopkins School
- 1:05:40Speaker 1: of Medicine, and everyone falls for it. Nobody calls up
- 1:05:44Speaker 1: Johns Hopkins and says it seems that this is a
- 1:05:46Speaker 1: stunning thing. Right time and time and time again, there
- 1:05:49Speaker 1: are these statements made, these claims made. Nobody does due diligence.
- 1:05:53Speaker 1: Nobody sees the technology, nobody sees the actual Well, open
- 1:05:57Speaker 1: up the machine. I can't like I would. It's one
- 1:06:00Speaker 1: of your Why the vcs walked because you have to
- 1:06:03Speaker 1: show us this and we can't give you money. This
- 1:06:05Speaker 1: is not this isn't a negotiating tactic. It's it's show
- 1:06:09Speaker 1: it us or we're out, because that's how we run. Yeah.
- 1:06:13Speaker 1: That the one of the Hopkins Lab scientists who attended
- 1:06:15Speaker 1: that this meeting back in the spring of two thousand
- 1:06:18Speaker 1: and ten at the end of the meeting, said to Elizabeth,
- 1:06:20Speaker 1: you know this is all well and good, but you know,
- 1:06:23Speaker 1: for us to really do a rigorous verification, you would
- 1:06:27Speaker 1: need to send us one of your devices. Either you
- 1:06:30Speaker 1: could leave this one or ship another one of them
- 1:06:32Speaker 1: to us. And then I'll want to have it in
- 1:06:34Speaker 1: my lab for several months and put it, you know,
- 1:06:39Speaker 1: pointed through its paces and compare it with the diagnostic
- 1:06:42Speaker 1: equipment that I have in my lab. And so he
- 1:06:44Speaker 1: encouraged her to do that, and she said she would.
- 1:06:46Speaker 1: And of course she promised a lot of stuff. It
- 1:06:49Speaker 1: never happened, never never happened. She promised data, she never delivered.
- 1:06:52Speaker 1: She promised documentation, never delivered. But we know why because
- 1:06:56Speaker 1: this thing was a fraud for years and years before.
- 1:07:02Speaker 1: How do you live like that? How does somebody not
- 1:07:04Speaker 1: expect to get caught? You know? Again, in her mind
- 1:07:08Speaker 1: goes back to the way that she channeled the traditional
- 1:07:11Speaker 1: Silicon Valley, and again that what I think it was.
- 1:07:14Speaker 1: The traditional Silicon Valley is the industry that grew out
- 1:07:17Speaker 1: of the computer chip industry, then became you know, the
- 1:07:20Speaker 1: personal computer revolution, and then the Internet boom, and now
- 1:07:23Speaker 1: it's the smartphone that's the traditional Silicon Valley. It's based
- 1:07:27Speaker 1: on coding, computer programming. And it's true that there's been
- 1:07:30Speaker 1: a lot of faking it until you make it. There's
- 1:07:33Speaker 1: been a lot of exaggerating, making exaggerated vae vaporware to
- 1:07:38Speaker 1: get the funding that you need to to make the
- 1:07:40Speaker 1: product happen. And she I think because she modeled herself
- 1:07:44Speaker 1: after jobs and to a lesser extent, Larry Ellison, she thought,
- 1:07:48Speaker 1: you know, this is the rule book that everyone goes
- 1:07:51Speaker 1: by in Silicon Valley, Like, it's not a big deal
- 1:07:54Speaker 1: if I go by it too. So, last question on
- 1:07:57Speaker 1: her prepping for this. I watched a couple of videos.
- 1:08:02Speaker 1: She always seems to speak like this in all of
- 1:08:04Speaker 1: our videos. It's this sort of weird baritone. And I
- 1:08:08Speaker 1: read a number of other articles that suggest that she
- 1:08:12Speaker 1: faked this deep voice for reasons known apparently only to herself.
- 1:08:18Speaker 1: What is the story with that? Is that her real
- 1:08:21Speaker 1: voice is that fake? Is this trying to be a
- 1:08:23Speaker 1: woman in a man's world? Like, what is what is
- 1:08:26Speaker 1: the deal with that it's not her real voice? Um?
- 1:08:29Speaker 1: And how do we know that for sure? So I'll
- 1:08:31Speaker 1: give you at least four data points. One is an
- 1:08:34Speaker 1: anecdote that I tell in the book. I think it's
- 1:08:37Speaker 1: in chapter eight of the book where an employee who
- 1:08:41Speaker 1: has just been hired to as an injury to work
- 1:08:44Speaker 1: as an engineer on the mini lab meets with her
- 1:08:47Speaker 1: in early two thousand eleven, and the meeting is at
- 1:08:49Speaker 1: the end of a long day. She's excited that he's
- 1:08:52Speaker 1: there and they're making progress on building this machine. And
- 1:08:55Speaker 1: she closes the meeting by getting up and and taking
- 1:08:58Speaker 1: her coat off her chair, and as she goes towards,
- 1:09:01Speaker 1: you know, to open the door of her office to
- 1:09:04Speaker 1: see him out, she lapses out of her baritone. She
- 1:09:08Speaker 1: forgets to put on the baritone and lapses into a
- 1:09:11Speaker 1: much more natural sounding young woman's voice. And he's totally
- 1:09:15Speaker 1: startled at this point because he's only heard her with
- 1:09:18Speaker 1: the baritone, and he he realizes at that point that
- 1:09:21Speaker 1: the voice is fake. He kind of turns it in
- 1:09:24Speaker 1: his head over the next couple of days and realizes,
- 1:09:27Speaker 1: you know, she must have decided this was necessary because, uh,
- 1:09:31Speaker 1: Silicon valleys a man's world, and she dropped out as
- 1:09:35Speaker 1: this young woman and that was so unusual. She must
- 1:09:38Speaker 1: have felt along the way that it was necessary to
- 1:09:40Speaker 1: get people's attention. Now, the other data points I have
- 1:09:43Speaker 1: are one is that um, as the book makes clear,
- 1:09:47Speaker 1: one of my sources for the book was Elizabeth's best
- 1:09:50Speaker 1: friend at Stanford, a young woman by the name of
- 1:09:53Speaker 1: Chelsea Burquette UM. And Chelsea says that Elizabeth's voice was
- 1:09:57Speaker 1: nothing like that at Stanford or even after Stanford. UM.
- 1:10:02Speaker 1: And so Chelsea herself believes that the voice is fake. UM.
- 1:10:06Speaker 1: A family member UM uh cooperated as well for the book.
- 1:10:11Speaker 1: And I'm not going to say this person's name, but
- 1:10:14Speaker 1: that person believes and and uh professes that he knows
- 1:10:18Speaker 1: for a fact that the voice is fake. And then
- 1:10:21Speaker 1: there's probably the most conclusive proof is that there's an
- 1:10:24Speaker 1: interview that she gave to the show Biotech Nation in
- 1:10:29Speaker 1: May of two thousand five. It's an NPR show. UM
- 1:10:32Speaker 1: and I have a recording of it. And at that point,
- 1:10:34Speaker 1: she's eighteen months out of Stanford. She's like twenty or
- 1:10:37Speaker 1: twenty one years old. Uh. She gives this interview to
- 1:10:40Speaker 1: Morrow Gunn and um Uh she sounds nothing like uh
- 1:10:45Speaker 1: the Elizabeth Holmes of later years. She sounds like this, uh,
- 1:10:51Speaker 1: this this kid almost who's speaking very fast, uh, in
- 1:10:56Speaker 1: a much more natural sounding young woman's voice, that's a
- 1:11:00Speaker 1: couple of pitches higher and uh, and you realize listening
- 1:11:05Speaker 1: to that audio recording that she basically at a certain
- 1:11:10Speaker 1: point after that decided to create a whole new persona
- 1:11:14Speaker 1: for herself, and and that changing her voice was part
- 1:11:16Speaker 1: of that new persona fashion. I always thought when you
- 1:11:19Speaker 1: close your b around, your voice changes, and that that
- 1:11:22Speaker 1: could have something to do with it. But you're saying
- 1:11:24Speaker 1: nothing to do with that whatsoever. It was for sure
- 1:11:28Speaker 1: a very part of a very contrived attempt to project
- 1:11:34Speaker 1: this uh you know, female Steve jobs Aura, which which
- 1:11:40Speaker 1: other than the other than the the black turtleneck. There
- 1:11:46Speaker 1: was just nothing in common whatsoever. But um, hey, what
- 1:11:51Speaker 1: are you gonna do that? That's was That was um
- 1:11:54Speaker 1: attempt and uh, just just astonishing. So I only have
- 1:11:59Speaker 1: you for a couple of more minutes. Let me jump
- 1:12:01Speaker 1: to my favorite questions that I ask all my guests.
- 1:12:05Speaker 1: Before I do that, I just have to say, we
- 1:12:07Speaker 1: covered a ton of stuff. Anything you want to bring up,
- 1:12:10Speaker 1: anything I might have missed you think is noteworthy. A
- 1:12:14Speaker 1: funny moment in this saga, which is uh, forty eight
- 1:12:19Speaker 1: hours after my first story is published in October two fifteen, Um,
- 1:12:24Speaker 1: Elizabeth and Sonny lead this all employee meeting. You have
- 1:12:28Speaker 1: that in the book, and that's it's amazing that people
- 1:12:31Speaker 1: just go along with that. Yeah. And I was told that,
- 1:12:35Speaker 1: you know, at least half of the employees in the audience,
- 1:12:38Speaker 1: uh didn't go along with it. And and uh, I
- 1:12:41Speaker 1: couldn't believe that this was actually happening. But then you
- 1:12:45Speaker 1: you did have some employees, many employees, who did go
- 1:12:48Speaker 1: along with it. And I think it speaks to the
- 1:12:50Speaker 1: culture of hubris arrogance. Uh. You know, us versus them,
- 1:12:57Speaker 1: we're above everything, Uh, even though we haven't really invented
- 1:13:01Speaker 1: anything new. Um. And and you know that that's it
- 1:13:05Speaker 1: really speaks to how broken the culture of that company was.
- 1:13:09Speaker 1: F you, Carrie row is what Bawani and Holmes lead
- 1:13:15Speaker 1: them on chanting? And how long does this go on?
- 1:13:18Speaker 1: And I think people told you about it was it
- 1:13:20Speaker 1: was just a couple of times, two or three chants, um.
- 1:13:25Speaker 1: And it had been preceded. There had been a precedent
- 1:13:28Speaker 1: three months prior after Aaroness had received FDA approval for
- 1:13:33Speaker 1: one of its fingerstick tests. One turned out the only
- 1:13:36Speaker 1: fingerstick tests that ever got approval for was a test
- 1:13:39Speaker 1: to detect HERPS, which is actually a pretty easy test
- 1:13:42Speaker 1: to do because it's just a test that says yes
- 1:13:44Speaker 1: or no, do you have the disease um. So those
- 1:13:47Speaker 1: tests are much much easier than than most lab tests,
- 1:13:50Speaker 1: which are quantitative tests. Anyways, Aarons had gotten this approval
- 1:13:54Speaker 1: from the f d A and was very very proud,
- 1:13:57Speaker 1: and Sonny had led employees in the Uteria in a
- 1:14:02Speaker 1: chant which I actually have on tape because I have
- 1:14:04Speaker 1: footage of that meeting, and he yeah, he had the
- 1:14:07Speaker 1: whole company yelling, and at that point the chant was
- 1:14:11Speaker 1: directed at Aronos's rivals Quest and Lab Corps, where the
- 1:14:16Speaker 1: two nine pound guerrillas in the in the lab never
- 1:14:19Speaker 1: for a second thought this little pissent company with a
- 1:14:22Speaker 1: fake technology was That's the most amazing thing is they
- 1:14:26Speaker 1: think these are their rivals. And these two companies couldn't
- 1:14:30Speaker 1: possibly care less about that. Well, I mean, by the
- 1:14:32Speaker 1: time she became famous, they certainly knew who she was.
- 1:14:37Speaker 1: And I think it, uh, it didn't escape them that
- 1:14:40Speaker 1: the valuation of Paris first disclosed and Fortune magazine in
- 1:14:45Speaker 1: June two fourteen was nine billion, which was essentially the
- 1:14:49Speaker 1: same you know, market capitalization that Quest and Labcorp had
- 1:14:54Speaker 1: so um that had to get their their attention, and
- 1:14:56Speaker 1: I know it did. But yeah, the the the amount
- 1:15:01Speaker 1: that the degree to which Elizabeth and Sonny were obsessed
- 1:15:05Speaker 1: with Quest and Lab Corp uh is uh exponentially greater
- 1:15:11Speaker 1: than uh, you know, than how concerned Question and lap
- 1:15:14Speaker 1: Court were with Paras. But anyways, that first chant was
- 1:15:19Speaker 1: directed at Quest and Lab Corps. And then three months later,
- 1:15:22Speaker 1: when my story came out, at the end of this
- 1:15:25Speaker 1: meeting in which Elizabeth and Sonny had both been very
- 1:15:28Speaker 1: defiant about how my reporting was false and about how
- 1:15:32Speaker 1: they would take the fight to the journal and to
- 1:15:35Speaker 1: the journalist, a senior software engineer asked Sonny if he
- 1:15:41Speaker 1: would lead them in a chant, and Uh, no, one
- 1:15:45Speaker 1: you know had to ask what the chant was. Everyone
- 1:15:48Speaker 1: knew based on what had happened three months prior, and
- 1:15:51Speaker 1: so Sonny was of course very happy to oblige and
- 1:15:56Speaker 1: lead the company for a second time in a chant. Uh.
- 1:16:00Speaker 1: And this time added my name after the F you,
- 1:16:03Speaker 1: which was convenient because it rhymed amazing, John carry row
- 1:16:07Speaker 1: your fake news. Let's um that's what he should have said. Um,
- 1:16:12Speaker 1: I think the book is not fake news, and it's
- 1:16:14Speaker 1: absolutely fascinating. Let's let's jump to to our favorite questions,
- 1:16:19Speaker 1: and I'm I'm going to skip around a little bit
- 1:16:21Speaker 1: because I know we're tied on time. Tell us about
- 1:16:24Speaker 1: some of your early mentors, so, uh, I would cite
- 1:16:30Speaker 1: a few people. One of them would be uh my
- 1:16:33Speaker 1: investigative team colleague Mark Merrimont. He's still at the Wall
- 1:16:37Speaker 1: Street Journal to this day and still does great work
- 1:16:41Speaker 1: for the Wall Street Journal. Um was he on one
- 1:16:43Speaker 1: of the Pulitzer Prize winning teams that you uh yeah,
- 1:16:46Speaker 1: he was actually uh he he uh lead wrote one
- 1:16:50Speaker 1: of the stories that was in a package on corporate
- 1:16:53Speaker 1: scandals in two thousand two that won the Pulitzer Prize
- 1:16:57Speaker 1: for Explanatory Reporting, and I lead wrote another one of
- 1:17:02Speaker 1: those stories. Um, but he he had been a mentor,
- 1:17:06Speaker 1: uh several years prior on my first ever uh investigative work,
- 1:17:11Speaker 1: which was unmasking a Belgian a speech recognition software company
- 1:17:16Speaker 1: called learn out in Hospital, which was the pride of
- 1:17:19Speaker 1: Flanders back then. And I was based in Brussels, and
- 1:17:22Speaker 1: and Mark and another journal colleague named uh jesse Eisener
- 1:17:26Speaker 1: had um uh smelled a rat and and started writing
- 1:17:31Speaker 1: about this company and they needed help from a reporter
- 1:17:33Speaker 1: on the ground in Belgium and sought out my help
- 1:17:36Speaker 1: and then we we ended up, you know, spending close
- 1:17:39Speaker 1: to a year unraveling the fraud of this company. And
- 1:17:42Speaker 1: I learned a ton from those twho's got two guys,
- 1:17:45Speaker 1: especially from Mark Merrimont and uh so he was a mentor.
- 1:17:49Speaker 1: And then, UM, I'm gonna name check another former colleague,
- 1:17:53Speaker 1: Mike Williams, who's now the UH investigative editor at UM
- 1:17:58Speaker 1: at UH Reuters and who's a long time Wall Street
- 1:18:02Speaker 1: Journal reporter and editor. He was my bureau chief in
- 1:18:06Speaker 1: Paris for several years and he was later the Page
- 1:18:09Speaker 1: one editor of the journal. And then of course Mike Sikonolfie,
- 1:18:12Speaker 1: who was my current editor on the Investor investigative team.
- 1:18:15Speaker 1: I would mention that Eisener went on to win the
- 1:18:18Speaker 1: first online Pulitzer for his work at a pro public
- 1:18:23Speaker 1: That's right. So um, a lot lots of Pulitzer Prize
- 1:18:27Speaker 1: UH winning journalists came out of out of his shop.
- 1:18:30Speaker 1: So who, um, let's talk about your favorite books. Bad
- 1:18:33Speaker 1: Blood is your first book? What do you read? Who
- 1:18:36Speaker 1: do you really enjoy? Fiction? Nonfiction? Right Blood related or not? So? Um,
- 1:18:43Speaker 1: I love nonfiction and I love UH page turning nonfiction.
- 1:18:50Speaker 1: One of my favorite books of all time is a
- 1:18:52Speaker 1: Civil Action, which I read in the in the late nineties. UH.
- 1:18:58Speaker 1: I think it's uh. The name of the author is
- 1:19:00Speaker 1: Jonathan Harror. I think he worked on that book for
- 1:19:02Speaker 1: seven years. UM. Another deeply reported book that I love
- 1:19:08Speaker 1: is Black Hawk Down by Mark Bowden. Uh an amazing
- 1:19:12Speaker 1: feat of reporting uh reconstructing uh what those soldiers went
- 1:19:18Speaker 1: through in Somalia. Uh. Just an unbelievable book. UM. I
- 1:19:24Speaker 1: I loved the the sort of definitive UH nonfiction book
- 1:19:30Speaker 1: about Wall Street and the eighties Barbarians at the Gate,
- 1:19:34Speaker 1: which was written by UH guys who at the time
- 1:19:39Speaker 1: worked for the Wall Street Journal, Brian Burrow and John Helliar.
- 1:19:42Speaker 1: They've long since moved on. UM. I am a big
- 1:19:48Speaker 1: fan of the former Wall Street Journal reporter and now
- 1:19:54Speaker 1: best selling author Eric Larson. UM. Among his books H
- 1:19:58Speaker 1: Devil in the White City were um. Uh. The latest
- 1:20:03Speaker 1: that I lead that I read by him is about
- 1:20:06Speaker 1: the Lusitania. UM. He's just a terrific writer. UM. And
- 1:20:11Speaker 1: I would say, UH an influence in terms of writing
- 1:20:15Speaker 1: UH non nonfiction probably my my biggest influence. So what
- 1:20:20Speaker 1: has changed since you became a journalist twenty years ago.
- 1:20:24Speaker 1: How do you how do you see the we know,
- 1:20:26Speaker 1: the industry, the business of journalisms have changed. What do
- 1:20:29Speaker 1: you see as different in the actual reporting? Well, the
- 1:20:34Speaker 1: one obvious thing is the rise of social media. Um uh,
- 1:20:40Speaker 1: it's it's there everywhere you turn, you know. Uh. Um.
- 1:20:45Speaker 1: People you investigate are on social media or use social media.
- 1:20:49Speaker 1: I used LinkedIn to make contact with ex Theoris employees,
- 1:20:54Speaker 1: one of them Tyler Schultz. Um and uh yeah, I
- 1:20:59Speaker 1: think that it's it's it's both a reporting tool, but
- 1:21:02Speaker 1: it's also a disinformation tool, as we see hint, hint
- 1:21:07Speaker 1: with the current administration, it's sort of a propaganda tool. Um.
- 1:21:12Speaker 1: Thinking of Twitter in particular, um uh and uh it's
- 1:21:17Speaker 1: got other sort of um effects on our craft, uh,
- 1:21:24Speaker 1: which some of which aren't so great, which is that
- 1:21:26Speaker 1: journalists spend a lot of time on Twitter, probably too
- 1:21:28Speaker 1: much time on Twitter instead of actually doing work. Um right,
- 1:21:34Speaker 1: and sometimes they appine on Twitter in a way that
- 1:21:38Speaker 1: that compromises their objectivity or person objectivity. Um. So yeah,
- 1:21:44Speaker 1: social media has been a game changer, I think for
- 1:21:46Speaker 1: for our profession. If I had to point to something,
- 1:21:50Speaker 1: so tell us about a time you failed and what
- 1:21:52Speaker 1: you learned from the experience. So when I was a
- 1:21:55Speaker 1: brand new reporter at the Wall Street Journal Europe and
- 1:22:00Speaker 1: uscles back in I think it was UM and the
- 1:22:04Speaker 1: Wall Street Journal Europe back then was separate from the
- 1:22:07Speaker 1: mother ship. UM. We had these these European and Asian
- 1:22:10Speaker 1: editions that were run separately. So I wasn't a full
- 1:22:13Speaker 1: fledged Wall Street Journal reporter. I was a Wall Street
- 1:22:15Speaker 1: Journal Europe reporter. And uh, with respect to this incident,
- 1:22:20Speaker 1: it was a good thing. I M a colleague and
- 1:22:23Speaker 1: I wrote a story about a business deal that we thought, um,
- 1:22:30Speaker 1: you know, we had learned about that that was basically
- 1:22:33Speaker 1: turned out to be complete fiction. Uh. And it was
- 1:22:36Speaker 1: like a comedy of errors. It was a a merger
- 1:22:41Speaker 1: or so we thought, between several post offices in Europe,
- 1:22:46Speaker 1: and um, you know, we had these sources who were
- 1:22:50Speaker 1: who were just you know, these pseudios, sources who were
- 1:22:53Speaker 1: several times removed from actual information, but who uh you know,
- 1:22:57Speaker 1: told us that they thought they knew what they couldn't
- 1:23:01Speaker 1: have known because it wasn't true. And so we we
- 1:23:04Speaker 1: wrote this this completely absurd story that was completely wrong
- 1:23:09Speaker 1: and erroneous. What was the take um was that what
- 1:23:13Speaker 1: was your takeaway? No, my takeaway was that, um, you
- 1:23:16Speaker 1: know you can't you you got to verify. I'm reading
- 1:23:20Speaker 1: Cy Hirsch's um Um autobiography right now, and he has
- 1:23:25Speaker 1: an expression for it that he learned at City News
- 1:23:28Speaker 1: in Chicago, where he started out his career, uh, which
- 1:23:32Speaker 1: is uh check it out. You know, he check it out.
- 1:23:36Speaker 1: And we didn't do any checking. We just went with
- 1:23:39Speaker 1: what you know, the first person we got on the
- 1:23:41Speaker 1: phone told us and the story was completely wrong. It
- 1:23:44Speaker 1: was embarrassing, and frankly, I just I still don't understand
- 1:23:46Speaker 1: why I wasn't fired for it. And what is it
- 1:23:49Speaker 1: that you know about investigative reporting today that you wish
- 1:23:52Speaker 1: you knew twenty years ago? I mean, I think earlier
- 1:23:57Speaker 1: in my career, I think that I thought investigative reporting
- 1:24:03Speaker 1: was a glamorous craft. You know this may sound um corny,
- 1:24:09Speaker 1: but um. One of the things that contributed to inspiring
- 1:24:12Speaker 1: me to become a newspaper reporter was reading All the
- 1:24:15Speaker 1: President's Men after college graduated in ninety four, and that
- 1:24:19Speaker 1: was one of the first books I read after college,
- 1:24:22Speaker 1: and uh, you know, I think it made uh investigative
- 1:24:26Speaker 1: journalism and reporting seemed glamorous to me. And what I
- 1:24:30Speaker 1: would caution you know, young people getting into this line
- 1:24:34Speaker 1: of work is that uh of the time, it's not glamorous.
- 1:24:39Speaker 1: It's digging. Uh you know, behind the scenes and the
- 1:24:43Speaker 1: dark in semi or complete obscurity. And um, you know,
- 1:24:50Speaker 1: hopefully you you you published some some good stories, but
- 1:24:53Speaker 1: oftentimes the stories won't have as much impact as you
- 1:24:58Speaker 1: would hope they would have. And you know, it can
- 1:25:02Speaker 1: be thankless work, and um, I would argue that it's
- 1:25:05Speaker 1: also also can be very rewarding work, but you gotta
- 1:25:09Speaker 1: stick with it, and it's uh work that requires persistence
- 1:25:13Speaker 1: and perseverance. UM. I don't know if I necessarily knew
- 1:25:17Speaker 1: all those things when it started out, just just fascinating.
- 1:25:20Speaker 1: Thank you, John for being so generous with your time.
- 1:25:23Speaker 1: We have been speaking with John Carrirew, author of Bad Blood,
- 1:25:28Speaker 1: Secrets and Lies in a Silicon Valley start up. If
- 1:25:31Speaker 1: you enjoyed this conversation, well then look up and intro
- 1:25:33Speaker 1: down an intro on Apple, iTunes, Overcast, Stitcher, or wherever
- 1:25:38Speaker 1: your final podcasts are sold, and you can see any
- 1:25:40Speaker 1: of our prior two hundred plus conversations. We love your
- 1:25:45Speaker 1: comments feedback and suggestions right to us at m IB
- 1:25:50Speaker 1: podcast at Bloomberg dot net. I would be remiss if
- 1:25:53Speaker 1: I did not thank my crack staff that helps to
- 1:25:55Speaker 1: put together this conversation each week. Medina Parwana is our
- 1:26:00Speaker 1: you engineer slash producer, Taylor Riggs is our booker and producer,
- 1:26:04Speaker 1: and Michael Batnick is our head of research. I'm Barry Retolts.
- 1:26:08Speaker 1: You've been listening to Masters in Business on Bloomberg Radio.